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Abstract of thesis entitled: Gene Expression Profiling of Ovarian 
Cancer 
Submitted by WONG Wai-yin 
for the degree of Master of Philosophy at The Chinese University of 
Hong Kong in June 2005 
Ovarian cancer has the highest mortality rate among the common gynecologic 
malignancies worldwide. In Hong Kong, ovarian cancer is the ninth common cancer, 
and the tenth most common cause of cancer death. The high case fatality rate is in 
part because most ovarian cancer patients present with advanced stage disease with 
malignancy which is essentially incurable. In order to obtain a whole genome 
assessment of aberrant gene expression in advanced ovarian cancer, we have used 
high-throughput Affymetrix Genechip® U133A oligonucleotide microarrays 
comprising over 22,000 human transcript probe-sets to profile 8 early stage, 20 
advanced stage serous primary carcinomas, and 4 metastatic carcinomas of ovary 
origin to look for novel molecular diagnostic and prognostic markers, and therapeutic 
targets for early detection and drug development. We identified 392 genes that were 
significantly differentially expressed between normal ovarian surface epithelium and 
ovarian cancer specimens (p < 0.01). We found 10 genes were significantly (p < 0.01) 
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differentially regulated in advanced-stage ovarian cancer compared to early-stage 
ovarian cancer while 20 genes were significantly (p < 0.05) differentially regulated in 
metastatic cancers when compared to primary ovarian cancers. The microarray data 
were validated using real time RT-PCR on 23 genes of most interest. They include 
CDC2, CKDNIC, DIRAS3 (ARHI), T0P2A, BIRC5, BUBIB, CCNAl, CCNB2, 
CCNEl, NEK2, TTK, HCAP-G, KNTC2, KPNA2 and REC8L1 from the comparison 
between cancers and normal controls; EGFL6, PEG 10, C0LJ3A, STXBP6 and 
PLOD2 from the comparison between advanced-stage and early-stage cancers; TNC, 
PLA U and SERPINEl from the comparison between metastatic cancers and primary 
cancers. Our microarray data was shown to be consistent with the real-time PGR 
results with respect to the direction of fold change of genes. The data provided here 
should contribute to a more profound understanding of tumorigenesis, progression, 
















鏈反應，這二十三個基因包括了 ••在癌症與正常對照的比較中有CDC2’ CKDN1Q 
DIRAS3 (ARHI), T0P2A, BIRC5, BUB1B, CCNA1, CCNB2, CCNE1, NEK2, TTK’ 
HCAP-G, KNTC2, KPNA2和REC8L1 ；在後期癌症與早期癌症的比較中有 







cDNA - complementary deoxyribose nucleic acid 
CGH - comparative genomic hybridization 
cRNA - complementary ribonucleic acid 
DNA - deoxyribose nucleic acid 
EGF - epidermal growth factor 
FDR - false discovery rate 
FGF 一 fibroblast growth factor 
FIGO - The International Federation of Gynecology and Obstetrics 
GAPDH - Glyseraldehyde-3-phosphate dehydrogenase 
GCH - comparative genomic hybridization 
GDP - guanine-di-phosphate 
GTP - guanine-tri-phosphate 
H & E - haemotoxylin and eosin 
IGF - insulin-like growth factors 
IM - ideal match 
IVT - in-vitro transcription 
LOH - loss of heterozygosity 
M a s -Micorarray Suite 
MBEI - model-based expression index 
M-CSF - macrophage-colony stimulating factor 
MM - mismatch 
MSI - microsatellite instability 
OC - Oral contraceptive 
OCT - optimal condition temperature 
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OSE - ovarian surface epithelium 
PCR - polymerase chain reaction 
PDGF - platelet-derived growth factor 
PM - perfect match 
ROC - risk of ovarian cancer 
RNA - ribonucleic acid 
rRNA - ribosomal ribonucleic acid 
RT-PCR - reverse transcription-polymerase chain reaction 
TGF - transforming growth factor 
tRNA - transfer ribonucleic acid 
VN -vitronectin 
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Gene expression profiling of ovarian cancer Chapter I. Introduction 
CHAPTER 1 INTRODUCTION 
Ovarian cancer ranks as the fifth leading cause of death from cancer and has the 
highest mortality rate among the common gynecologic malignancies worldwide 
(Pecorelli, 2000). In Hong Kong, ovarian cancer ranks as the ninth common cancer, 
and the tenth most common cause of cancer death in female (William, 2000). Every 
year approximately 25,000 ovarian cancer cases are newly diagnosed and 
approximately 15,000 deaths occur secondary to the malignancy in the United Stage. 
(Landis et al.，1999). The early detection of ovarian cancer continues to elude 
clinicians and scientists. The seriousness of this problem is illustrated by the 5-year 
survival rate is 95 percent for women with stage I disease but only 40 percent for 
women with stage III/IV disease (Holschneider et al., 2000; Marsden et al., 2000). 
Clearly, the detection of ovarian cancer at its earliest stages should 
significantly affect survival rate. The only validated marker in current use for the 
management of ovarian cancer is CA125, which can be detected in the serum of 
more than 80 percent of women with ovarian carcinomas. But it is neither sensitive 
nor specific enough for population screening to detect early, treatable ovarian 
cancers (Jacobs et al , 1993). Moreover, the currently available chemotherapy is not 
usually capable of achieving cure in malignant ovarian cancer. 
The search for serum markers that would enable earlier detection of the 
disease and its metastasis, and the therapeutic targets of drugs development and 
novel therapy has been aided by high-throughout techniques, including 
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transcriptional profiling using cDNA microarrays, which allows simultaneous 
analysis of tens of thousands of expressed genes derived from a single tumor sample. 
1.1. Classification of common epithelial ovarian tumors 
According to the World Health Organization's (WHO) Classification based 
on the histological appearances, this classification categorizes ovarian tumors with 
regard to their derivation fi-om coelomic surface epithelial cells, germ cells, and 
mesenchyme (the stroma and the sex cord). Human ovarian tumors can be classified 
into three predominant classes: surface epithelial-stromal tumors, germ cell tumors 
(derived from oocytes), and sex cord-stromal tumors. Apart from these three major 
classes, some minor ovarian tumors are classified in accordance with whether their 
histogenesis is undetermined, their histology is non-specific, or they are metastatic to 
the ovary. The most common neoplasm of the ovary is composed principally of 
epithelial cells. Epithelial tumors account for at least 50 percent of all benign ovarian 
neoplasm, and from 85 to 90 percent of the primary malignant tumors. Whereas germ 
cell and sex cord-stromal tumors only account for 5 percent each. Since surface 
epithelial ovarian tumors are the most predominant class and the specimens studied 
in the report are of such histological type, only this class is discussed in this section. 
Surface epithelial-stromal tumors composed of one or more of the several 
distinctive types of epithelium and stroma in a variety of combinations. These tumors 
are generally considered to arise from the surface epithelium of the ovary or its 
derivatives, the surface epithelial inclusion glands and the adjacent ovarian stroma. 
The tumors derived from undifferentiated cells in the surface epithelium of the 
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postnatal ovary would retain a potentiality for differentiation along the same 
pathways as did their embryonic precursors. Hence, a neoplasm derived from these 
cells could differentiate along various Miillerian pathways. Consistent with the 
Miillerian differentiation of the epithelial surface during the transformation to 
neoplaisa, five major histological subtypes of epithelial tumors are categorized. They 
are serous tumors, mucinous tumors, endometrioid tumors, clear cell tumors, 
transitional cell tumors (Brenner tumors), mixed epithelial tumors, and 
undifferentiated carcinosarcoma. 
Surface epithelial tumors are further sub-classified into benign, borderline 
and carcinoma depending on the degree of epithelial proliferation and the presence or 
absence of stromal invasion. Benign epithelial tumors are often associated with 
epithelial inclusion cysts. Such tumor types are found in women of all ages, but are 
most prevalent during the reproductive years. They are most commonly unilateral. 
The term 'borderline' is used in the new WHO classification. Borderline ovarian 
epithelial tumors (or epithelial ovarian tumors of low malignant potential) are a form 
intermediate between one that is morphologically clearly benign and one that is 
obviously malignant. This type of tumor has some, but not all, of the morphological 
features of malignancy. The epithelial malignant tumors of the ovary represent 
almost 90 percent of all ovarian malignancies. The malignant forms of ovarian 
tumors are metastatic and show stromal invasion. The mortality of patients with 
malignant ovarian tumors is high. 
In this section, only the four most common types are discussed, they are 
serous tumors, mucinous tumors, endometrioid tumors and clear cell tumors. 
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1.1.2. Serous tumors 
The serous tumors are by far the most commonly encountered histological 
type, comprising about 40 percent of all primary ovarian neoplasms (Abell, 1966). 
Serous carcinomas tend to be large tumors. Grossly, the majority are papillary and 
cystic with multiple friable papillary masses and solid nodules of adenocarcinoma 
obliterating the cystic cavities and invading adjacent ovarian parenchyma. The fluid 
within the cysts tends to be watery and thin or ‘serous’ in quality. Serous neoplasms 
are composed of cells that resemble those of the surface epithelium of the ovary or of 
the fallopian tubal mucosa. 
The well-differentiated (low grade) carcinomas are usually papillary 
cystadenocarcinomas. They have broad and finely branched papillations with 
connective tissue stroma. Overgrowth of epithelial cells results in anastomosing 
bridges of tumor cells that interconnect adjacent papillae. Nuclei are large, vesicular 
and have prominent nucleoli. Moderately and poorly differentiated carcinomas have 
more alveolar and medullary configurations, with solid sheets of cells surrounding 
irregular small spaces; cysts and papillae are less conspicuous. The least 
differentiated and most aggressive variants are predominantly solid adenocarcinomas. 
They contain undifferentiated cells and large bizarre cells. 
Some serous tumors produce mucus. Unlike mucinous cell tumors, however, 
the mucin is extracellular and appears to be secreted into the cysts from the apical 
surfaces of the epithelial cells. 
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1.1.2. Mucinous tumors 
Ovarian cysts lined by mucin-rich epithelial cells form a common variety of 
benign cystoma. Most mucinous tumors are comoposed of endocervical type cells. 
Often, the tumors contain goblet cells similar to those of gastrointestinal mucosa. 
Gastrointestinal enzymes and polypeptides can be found in tumor fluid and tissue. 
Some of the endocervical-like cells may actually represent mucinous cells of the 
stomach or Brunner's glands. Grossly, mucinous tumors may attain huge proportions. 
The capsular surface is usually smooth. Cyst fluid is mucoid and tenacious, but one-
fourth of the cysts may also contain serous fluid. 
Greater variations in degree of differentiation occur in mucinous tumors than 
in most ovarian epithelial neoplasms. Benign cystadenomas may have small, 
localized areas of carcinoma which require extensive sampling to identify. Most 
carcinomas consist of multiple glands and cysts of variable size lined by malignant 
mucinous cells. Stromal invasion is often difficult to recognize in mucinous tumors 
because of their complex multilocular patterns, with closely packed glands of various 
sizes. In tumors without an obviously invasive component, a diagnosis of carcinoma 
is also warranted whenever the atypical cells lining the cysts are severely anaplastic, 
stratified into more than three layers, form intraglandular bridges or produce a 
cribriform pattern. With increasing malignancy, the amount of intracytoplasmic 
mucin diminishes, and recognition of the tumor as a mucinous adenocarcinoma 
becomes dependent on finding better differentiated areas. 
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1.1.2. Endometrioid tumors 
Endometrioid tumors have the microscopic features of one or more of the 
typical forms of endometrial neoplasia. Endometrioid carcinomas tend to be less 
cystic than serous or mucinous carcinomas. Solid nodular areas of yellow-tan to dark 
red tissue often alternate with cysts, or comprise the bulk of the tumor. 
The vast majority of the diagnostic microscopic features of endometrioid 
carcinomas are relatively well-differentiated adenocarcinomas with tubular of 
branching glands. However, all the subtypes of endometrial carcinoma may be 
observed, including poorly differentiated medullary tumors that are difficult to 
recognize as endometrioid carcinoma. When papillary is observed, the papillae are 
blunt and broad, in contrast to the finer branching, slender papillations of serous 
carcinomas. Squamous metaplasia or differentiation is characteristic of endometrioid 
carcinoma, occurring in one-fourth to one-half of cases (Russel, 1979). Occasionally, 
most or practically all of the tumors appear as squamous cell carcinomas. Mucin 
production is sometimes prominent. Typically, the mucin is predominantly 
extracellular or periapical. 
1.1.2. Clear cell tumors 
Clear cell carcinomas account for about 5 to 11 percent of all ovarian 
carcinomas. Grossly, the tumors usually exceed 15 cm in diameter and are a mixture 
of cystic and solid tissues. Clear cell carcinoma is one of the commonest types of 
carcinoma originated from the epithelium of endometriosis. Microscopically, clear 
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cell carcinomas have numerous distinctive architectural and cellular patterns. Cells 
with abundant clear or vacuolated cytoplasm containing abundant glycogen are 
arranged diffusely in solid sheets, line tubular glandular or cystic spaces, or cover 
papillary projections. Most tumors have a mixture of patterns. Glomerulus-like tufts 
sometimes protrude into microcysts. Clear cells are typically present but usually are 
mixed with other cell types. A variant of the clear cell has scanty cytoplasm draped 
around a prominent protruding nucleus, producing the so-called hobnail cell. 
Frequently, the carcinoma cells are not vacuolated but have abundant eosinophilic, 
granular cytoplasm. Intracellular mucin is absent or very scant, but mucinous 
secretions are often found within tubular lumens. Mixtures with other miillerian cell 
types, such as endometrioid or serous carcinomas, are said to be frequent. 
1.1.2. Cancer staging 
The function of staging system for any type of cancers is to reflect the 
biological behavior of the specific cancer by classifying patients into prognostic 
subgroups based on the extent of tumor spreading of the disease and other factors. 
Accurate staging provides advantages for treatment planning and facilitates the 
comparison of data between institutions. However, clinical signs and symptoms are 
notoriously misleading and often underestimate the true extent of disease. For 
example, other cancers and nonmalignant conditions such as fibromas, 
endometrioisis, or tuberculosis show similar signs and symptoms of ovarian cancer 
(Moore, 1993). In 1987，the International Federation of Gynecology and Obstetrics 
(FIGO) adopted a revised staging system for ovarian cancer (Table 1.1) which took 
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multiple prognostic variables, such as tumor distribution and volume, tumor rupture, 
malignant cytology, and lymph node metastasis into account. While histological type, 
tumor grade, DNA content, hormone receptor status, and residuum after 
cytoreductive surgery are not considered in the FIGO staging system (Moore, 1993). 
1.1.2. Tumor grading 
Tumor grade is an essential prognostic variable with regard to responds to 
therapy and disease-free survival in malignant ovarian tumors. Practically, 
pathologists employ an architectural grading system adopted by the FIGO that is 
based upon the glandular pattern of the ovarian tumors. Grade I carcinomas are well 
differentiated and are predominantly glandular. Grade II carcinomas are moderately 
differentiated and are 50 percent glandular, while grade III carcinomas are poorly 
differentiated and are predominantly solid. The degree of differentiation is related to 
the proportion between epithelial and connective tissue (the more epithelial, the more 
the differentiation) and to the cellular atypia. 
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Table 1.1 Surgical stages of ovarian cancer according FIGO staging system. 
Stage Description 
I Limited to the ovaries 
la One ovary involved 
lb Both ovaries involved 
Ic One or both ovaries involved, but with cancer on the 
surface of an ovary, rupture of an ovarian cyst malignant 
ascites or positive abdominal washings 
II Spread to adjacent pelvic structures 
lia Spread to uterus of fallopian tubes 
lie Spread to pelvic peritoneum 
III Spread to the upper abdomen 
Ilia Microscopic spread to the upper abdomen 
Illb Cancer nodules less than 2 cm in the abdomen 
IIIc Nodules more than 2 cm, or positive pelvic or aortic 
lymph nodes 
IV Distant spread beyond the abdomen, liver, lung, etc. 
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1.2. Etiology 
The exact etiology of ovarian cancer still remains unknown, several factors, 
however, have been consistently associated with increased and decreased risks of the 
disease. 
1.2.2. Factors associated with increased risks 
Family history. Epithelial ovarian cancer can occur as a sporadic event in 
women who have no family history of ovarian neoplasia, but several clinical and 
epidemiological studies have shown women who have a family history are at 
increased risk of suffering from ovarian cancer. Lynch et al. (1990) have estimated 
that approximately 5 to 10 percent of ovarian cancer might be due to hereditary 
factors. Three hereditary syndromes which familial aggregation of ovarian cancer 
occurs have been described by Lynch et al. (1993), they are the site-specific ovarian 
cancer syndrome, the breast-ovarian cancer syndrome, and the hereditary non-
polyposis colorectal cancer syndrome (Lynch Syndrome II). These three hereditary 
syndromes are associated with a significantly earlier onset of ovarian cancer than 
those patients without family histories (Lynch et al., 1991). However, the occurrence 
of familial cancer accounts for only a small proportion of ovarian cancer cases 
(Parazzini et al., 1992). This suggests that although family history increases the risk 
of malignant ovarian cancer, other factors responsible for ovarian carcinogenesis 
may exist. 
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Dietary factor. The incidence of ovarian cancer was three-fold higher in 
women who consumed significantly more yogurts and cottage, which have 
considerable levels of lactose (Cramer et al.，1989). On the other hand, the serum 
levels of galactose-1 -phosphate uridyltransferase were significantly lower among 
patients with ovarian cancer compared with the control groups. Based on these 
findings, it is proposed that populations that consume a high fat-galactose diet but 
lack the enzyme galactose-1 -phosphate uridyltransferase to breakdown galactose to 
glucose may result in overexposure of ovary to increasing levels of galactose. 
Association between ovarian cancer and animal fat content in milk was also 
evaluated. The relative risk for ovarian cancer for those who drank more than one 
glass of whole milk each day was three times higher than those never drank whole 
milk. Among patients who drank milk regularly, those who drank only whole milk 
were at increased risk compared with those who drank milk with 0 % or 2 % milk 
(Mettlin and Piver, 1990). 
Infertility and fertility drugs. An increased risk of ovarian cancer among a 
cohort of infertile women was observed in many studies (Whittemore et al, 1992; 
Rossing et al., 1994; Venn et al , 1995). On the other hand, an increased association 
between the use of fertility drugs and the incidence of borderline ovarian tumors was 
revealed (Harris et al., 1992; Rossing et al., 1994). Moreover, infertile women treated 
with fertility drugs are at high risk of ovarian cancer compared to women without a 
history of infertility, whereas infertile women who do not use fertility drugs were not 
at increased risk (Whittemore et al., 1992), suggesting a role of fertility drugs in the 
etiology of ovarian cancer. 
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1.2.2. Factors associated with decreased risks 
Pregnancy. Pregnancy has been associated with a lower risk of ovarian 
cancer. The more pregnancies a woman has, the less is her chance of developing 
ovarian cancer (Fox and Singh, 2002). It is of note, however, that the first pregnancy 
has a greater protective effect than later pregnancies, and that the pregnancy need not 
be completed. Failed gestation (e.g. ectopic pregnancies and abortions) also reduces 
the risk of ovarian cancer, although the magnitude of protection is less than that 
obtained from a full-term pregnancy. A theory proposed by Fathalla (1971) named 
"incessant ovulation theory" explains the protective effect of pregnancy. It proposed 
that the repeated episodes of proliferation of surface epithelium may provide cells 
already bearing allelic loss and those carrying inactivated tumor suppressor genes 
with chances to increase their cell numbers. This may lead to uncontrolled cell 
division and malignant transformation. Therefore, pregnancy provides a rather long 
period of time for the surface epithelial cells to take a rest by ceasing ovulation. 
Breast-feeding. Breast-feeding also decreases the risk of ovarian cancer. 
Women who have breastfed after pregnancy would be at lower risk in ovarian cancer, 
and the measure of protection increases with the length of the breast-feeding period. 
The estimated decrease in risk is 0.99 with every month of breast-feeding 
(Whittemore et al.，1992). In addition, the reduction in risk conferred by breast-
feeding is larger in the first six months after delivery than the reduction observed 
with subsequent months of lactation. 
Tubal ligation and hysterectomy. Survey conducted by Whittemore et al. 
(1992) showed significant reduction in invasive epithelial ovarian cancer risk 
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associated with tubal ligation. Hysterectomy with ovarian conservation has also 
shown an inverse association with ovarian cancer risk in several studies (Irwin et al., 
1991; Weiss and Harlow, 1986). The protective effect of tubal ligation and 
hysterectomy could be explained in the way that they might block the ascent of 
carcinogenic agents such as asbestos, viruses, or contraceptive foams or gels into the 
peritoneal cavity. 
Oral contraceptives (OCs). In a very large number of studies, they showed 
that the use of combined OCs diminished considerably the risk of ovarian cancer, 
and the magnitude of the risk reduction increased with lengthening duration of usage 
(Fox and Singh, 2002). The effect of OCs on ovarian cancer risk persisted for at least 
10 to 15 years after use has been ceased, but the protective effect of OCs usage was 
most marked in older women. The protection, presumably, like pregnancy, reflects 
long-term suppression of ovulation, 
1.2.3 Other factors 
Genetic factors. Genetic factors are clearly important in the etiology of 
ovarian cancer, they are discussed in the following sections. 
1.3. Understanding of progression of ovarian carcinoma 
The specific events evolved in cancer progression phase are poorly understood 
primarily because of the multiplicity of changes that occur, examples of such process 
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are neo-angiogenesis and desmoplasia (i.e. stimulation of fibroblast proliferation and 
deposition of extracellular matrix in the surroundings of islands of tumor cells). 
Additionally, the genome becomes unstable as the cancer progresses, causing 
chromosomal alterations with increasing frequency. These lesions do not accrue 
randomly, and tumors often show remarkable uniformity in their chromosomal 
aberrations. In nearly every category of tumors, specific primary and secondary 
chromosomal alterations are consistently observed and may contribute to the 
progression process (Perantoni, 1998). As the progression phase ends, tumor cells 
have converted to the neoplastic phenotype. They are invasive, sometimes metastatic, 
and highly autonomous. They can now erode their surrounding normal tissue barriers, 
penetrating cellular layers as well as the basal laminar matrices. They can escape 
both physical and growth regulatory restraints. 
Cancer metastasis is a complex multi-step process. Unrestrained cancer cell 
proliferation dose not, by itself, appear to lead to metastasis. Rather, the tendency of 
malignant cells to cross tissue boundaries which distinguishes proliferative disorders 
and carcinomas in situ from true malignancy lead to metastasis (Liotta et al.’ 1991; 
van Roy and Mareel, 1992). The several interdependent processes resulting 
metastasis include detachment of cancer cells from their original localization, cancer 
cell migration, invasion of cancer cells into the surrounding tissue, access of cancer 
cells to blood and lymphatic vessels, and adhesion to and invasion through the 
endothelium thus allowing colonization at distant sites in the organism. Cancer cells 
and normal cells have no qualitative differences with respect to the basic processes of 
cell detachment, cell migration, cell invasion and the formation of colonies at distant 
sites. The difference is that cancer cells express the phenotypic traits characteristics 
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for these processes at times and places incompatible with normal cellular behavior 
(Werb et al., 1990; Liotta et al., 1991; van Roy and Mareel, 1992). The process of 
metastasis requires progressive genetic changes and molecular interactions of tumor 
suppressor genes and oncogenes. Previous studies indicated that genes of adhesion 
molecules (e.g. CD44, integrins, and E-cadherin), cytokines (e.g. IL-6 and TGF-/32), 
angiogenic factors (e.g. VEGFP and PD-ECGF), and signal transduction molecules 
might play an important role in metastasis (Skubitz, 2002; Nash et al., 1999). 
1.4. Current screening test for ovarian cancer 
Two distinct strategies have emerged to detect ovarian cancer in women: one 
ultrasound based, with transvaginal scanning as the primary test, and the other blood 
based, with measurement of the serum tumor marker CA125 as the primary test and 
ultrasound as the secondary test (i.e. multimodal screening). 
1.4.1 Transvaginal ultrasound 
Transvaginal ultrasonography is used in all screening strategies, either as the 
sole screening modality or as a secondary test in multimodal screening. The aim is to 
detect the earliest possible architectural changes in the ovary that accompany 
carcinogenesis. Both ovarian volumes range from 10 mm to 20 mm, depending on 
menopausal status. Persistence of ultrasound features on repeated scanning six to ten 
weeks following detection of abnormalities on the initial screening scan helps 
reducing false-positive rates. Most screening protocols use a weighted scoring 
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system or morphological index based on ovarian volume, outline, presence of 
papillary projections, and cyst complexity. The use of ovarian morphology to 
interpret pelvic ultrasound may increase sensitivity, and use of complex ovarian 
morphology may increase the positive predictive value of a multimodal screening 
strategy. 
1.4.2. Serum tumor markers 
At present, serum CA125 is the tumor marker most extensively investigated 
in ovarian cancer screening. It is the standard to which new screening markers for 
ovarian cancer must be compared. CA125 is an antigen expressed by fetal amniotic 
and coelomic epithelium. In adult, it is found in tissue derived from coelomic 
epithelium and Mullerian epithelium. The surface epithelium of normal fetal and 
adult ovaries does not express the determinant, except in inclusion cysts, areas of 
metaplasia, and papillary excrescences. The rate of decline in CA125 during primary 
chemotherapy has been an important independent prognostic factor in several 
multivariate analyses. Persistent elevation of CA125 at the time of a second surgical 
surveillance procedure predicts residual disease with higher than 95 percent 
specificity. Rising CA125 values have preceded clinical detection of recurrent 
disease by at least three months in most, but not all studies. Given the modest activity 
of salvage chemotherapy, this information has not impacted on survival yet. Rising 
CA125 during subsequent chemotherapy has been associated with progressive 
disease in more than 90 percent of cases. CA125 may serve as an effective surrogate 
marker for clinical response in phase II trials of new drugs. CA125 levels can aid in 
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distinguishing malignant from benign pelvic masses, permitting effective triage of 
patients for primary surgery. 
With a cutoff of 30 U/mL to 35 U/mL, which results in a sensitivity of 50 to 
60 percent for early disease, CA125 specificity approaches 99 percent in apparently 
healthy postmenopausal women. The specificity is lower in premenopausal women 
and in women with benign gynecologic conditions, including ovarian cysts, 
endometriosis, and uterine fibroids, which are part of the differential diagnosis for 
ovarian cancer. CA125 levels are elevated in women with hepatic disease, renal 
failure, and pancreatitis, which may alter clearance of the antigen or irritate the 
serosa of the peritoneum or pleura. Notably, the sensitivity of 99 percent for CA125 
is far lower than the 99.7 percent required for a positive predictive value of 10 
percent. 
Early detection of ovarian cancer remains the most promising application of 
CA125. An algorithm has been developed that estimates the risk of ovarian cancer 
(ROC) based upon the level and trend of CA125 values. A major trial has been 
initiated that uses the ROC algorithm to trigger transvaginal sonography and/or 
subsequent laparotomy. Such a trial could demonstrate improvement in survival 
through early detection. This strategy should provide adequate specificity, but 
sensitivity for early stage disease may not be optimal. 
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1.5. Molecular basis of ovarian cancer 
The exact etiology of ovarian cancer remains unknown. However, most 
epithelial ovarian cancers, like other sporadic cancers, are thought to develop due to 
the accumulation of genetic alterations with time. It makes the cell become less 
responsive to growth-inhibiting signals and undergo unscheduled cell division 
(Cavenee and White, 1995). Most epithelial ovarian cancers generally are 
monoclonal disease that originates in a single ovarian surface epithelial cell (Jacobs 
et al., 1992; Mok et al., 1992). And multiple genetic alterations should occur during 
malignant transformation of a single ovarian surface epithelial cell (Bast et al., 1995). 
Many genetic changes are involved in the development of both sporadic and 
hereditary cases of ovarian cancer. The genetic changes basically are related to the 
activation of oncogenes and inactivation of tumor suppressor genes, which are 
involved in regulating the balance between cellular proliferation, senescence, and 
apoptosis. 
1.5.1 Loss of heterozygosity 
Ovarian cancers exhibit a high degree of genetic disruption that is manifest at 
both the chromosomal and molecular levels. Studies using a technique called 
comparative genomic hybridization (CGH) have confirmed that most ovarian cancers 
have gains or losses of large segments of chromosomes. Smaller regions of allelic 
loss at specific genetic loci can frequently be detected using loss of heterozygosity 
(LOH) analysis. LOH has been demonstrated a high frequency losses of many 
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chromosomal arms, including 5q, 6q, 7p, llp-q, 13q, 14q, 16q, 17p-q, 22q and others 
(Alvarez and Berchuck, 2002). 
1.5.2. Microsatellite instability 
The presence of microsatellite instability (MSI) in ovarian cancer has been 
well documented by some investigators (Sood et al., 1996; Arzimanoglou et al , 1996; 
Colella et al., 1998; Codegoni et al , 1999; Johannsdottir et al., 2000). The frequency 
of MSI ranges from a low of 3.8 percent to a high of 37 percent depending on the 
markers studied. Germ-line defects in DNA mismatch repair genes result in a DNA 
replication error that is detectable as generalized instability of shout, tandemly 
repeated DNA sequences, known as microsatellites, which occur ubiquitously 
throughout the genome. hMLHl, hMSH2, hMSH3, hMSH6, PMSl, and PMS2 are the 
mismatch repair genes mostly associated with MSI in ovarian cancer, where hMLHl 
promoter hypermethylation is highly associated with high-frequency MSI (MSI-H) 
(Geisler et al , 2003). 
1.5.3 Oncogenes 
Oncogenes encode proteins normally involved in stimulating cell 
proliferation, but the over-activation of the gene products contributes to the process 
of malignant transformation. They are considered dominant transforming genes as 
the activation due to alterations in only a single allele of the gene can cause cell 
transformation. Oncogenes can be activated through several mechanisms, e.g. 
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amplification, point mutation, translocation and deletion. Most of the products of 
oncogenes are the proteins involved in the cascades of molecular events of signal 
transduction that lead to cell proliferation. 
Growth factors. A number of various growth factors express in ovarian 
cancers, e.g. epidermal growth factor (EGF) and its family, transforming growth 
factor-alpha (TGF-a) and its family, platelet-derived growth factor (PDGF), insulin-
like growth factors (IGFs), fibroblast growth factor (FGF) and macrophage-colony 
stimulating factor (M-CSF) (Alvarez and Berchuck, 2002). EGF is a large receptor 
family expressed in ovarian epithelium, which interacts with a large number of 
peptide growth factors with high affinity. C-erbB 1, YiEK-Hneu and c-fms are 
examples of genes that encode growth factor receptors (Katso et al., 1997). 
G proteins. G proteins are one of the classes of molecules involved in 
transmission of growth stimulatory signals toward the nucleus (Gutkind, 1998). They 
are located on the inner aspect of the cell membrane and have intrinsic guanine-
triphosphatase (GTPase) activity that catalyzes the exchange of guanine-triphosphate 
(GTP) for guanine-diphosphate (GDP). In their active GTP bound form, G proteins 
interact with kinases that are involved in relaying the mitogenic signal. The ras 
family of G proteins is among the most frequently mutated oncogenes in human 
cancers (Alvarez and Berchuck, 2002). Yi-ras mutations are common in borderline 
epithelial ovarian tumors, occurring in 20 to 50 percent of cases (Mok et al., 1993)， 
and mucinous ovarian cancers (Enomoto et al., 1990). The fact that K-簡 mutations 
are commonly detected in borderline ovarian tumors suggests that K-ras mutation 
may represent an early genetic alteration involved in the ovarian epithelial cells 
tumorigenesis. 
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Transcription factors. Activation of nuclear transcription factors responsible 
for DNA replication and cell division is the target of most of the signal transmission 
events. These transcription factors can act as oncogenes when they are 
inappropriately over-expressed. Among the nuclear transcription factors involved in 
stimulating proliferation, over-expression of members of the myc family has most 
often been implicated in the development of human cancers (Facchini and Perm, 
1998; Bouchard et al , 1998). Amplification of the c-myc oncogene has also been 
found in some epithelial ovarian cancers, where c-myc over-expression was more 
frequently observed in advanced stage serous adenocarcinomas, suggesting its role in 
tumor progression (Alvarez and Berchuck, 2002). 
1.5.4 Tumor suppressor genes 
Tumor suppressor genes encode proteins normally involved in inhibiting 
proliferation, and loss or inactivation of these genes plays a role in the development 
of most cancers. They are recessive genes that both alleles must be inactivated in 
order to exert a phenotypic effect on tumorigenesis (Knudson, 1997). Loss or 
inactivation of these genes can occur through point mutation, deletion, mitotic 
recombination, chromosomal loss, etc. (Katso et al., 1997). Most tumor suppressor 
gene products are nuclear proteins. 
p53. p53 is a tumor suppressor gene located on the short arm of chromosome 
17 (Miller et al., 1986). Thep53 gene encodes a nuclear protein that appears to play a 
central role in the regulation of both proliferation and apoptosis (Lamb and Crawford, 
1986). p53 normally interacts with a variety of proteins involved in transcriptional 
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regulation, DNA repair, cell-cycle progression, apoptosis, and proteosome-mediated 
protein degradation. If the cell exhibits genetic damage, the p53 protein acts to 
suppress cell growth by delaying entry into S-phase of the cell cycle so that the cells 
have more time for DNA repair (Finlay et al., 1989). It binds to transcriptional 
regulatory elements of genes, such as the cyclin-dependent kinase (cdk) inhibitor p21, 
that act to arrest cells in Gi phase (Alvarez and Berchuck, 2002). Beyond simply 
inhibiting proliferation, normal p53 is thought to play a role in preventing cancer by 
stimulating apoptosis of cells that have undergone excessive genetic damage 
(Kuerbitz et al., 1992). 
Alteration of the p53 tumor suppressor gene is the most frequent genetic 
event described thus far in ovarian cancer (Marks et al., 1991; Kohler et al., 1993; 
Eltabbakh et al., 1997). The prevalence of over-expression of mutant p53 is 
significantly higher in advanced ovarian cancer relative to benign cases (Alvarez and 
Berchuck, 2002). In addiction, p53 inactivation is uncommon in borderline tumors 
(Berchuck et al., 1994). 
BRCAl and BRCA2. BRCAl gene has been identified to be important in 
ovarian carcinogenesis. Inherited mutations of the BRCAl gene on chromosome 17q 
are involved in a significant fraction of hereditary ovarian cancers (Takahashi et al., 
1995). The BRCAl gene encodes an 1863 amino acid protein with 4 functional 
domains. Missense mutations in the BRCAl N-terminal RING domain have been 
reported in inherited breast cancer and sporadic ovarian cancer (Miki et al. 1994; 
Merajver et al. 1995), suggesting a critical role for the RING domain, which bind 
zinc and mediate binding of the protein to either another protein or to DNA, in the 
BRCAl function. The C terminus of BRCAl contains two 95-residue BRCT 
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(BRCAl C-terminal) domains, which were also found in many other proteins 
involved in DNA repair and cell cycle regulation (Koonin et al.，1996). The loss of 
heterozygosity on 17q in breast and ovarian tumors invariably involves the wild-type 
chromosome supported the hypothesis that cancers in BRCAl-linked families result 
from the inheritance of an inactivated mutation in one copy of the gene followed by a 
somatic loss of the wild-type gene on another chromosome (Smith et al., 1992). 
Some cases of hereditary ovarian cancer are also apparent in breast cancer 
families linked to the BRCAl gene (Boyd and Robin, 1997). BRCA2 gene encodes a 
3418 amino acid protein with 2 functional domains. BRCA2 binds directly with 
RAD51 (Sharan et al., 1997; Wong et al., 1997)，a eukaryotic homolog of bacterial 
RecA essential for double-strand DNA breaks repair by homologous recombination. 
It occurs primarily through the eight repeats of �4 0 amino acid BRC motifs in 
BRCA2. Recent evidence suggests that BRCA2 works directly to regulate the 
availability and activity of RAD51, consistent with the high stoichiometry of their 
binding (Davies et al., 1991). It implies that the loss of function of BRCA2 will 
increase the chromosomal instability. 
The BRCAl and BRCA2 protein levels are highest during S-phase， 
suggesting functions during DNA replication. The expression of BRCAl gene in 
ovarian and breast cancer cell lines abrogates the transformed phenotype and reduces 
tumor formationin nude mice, providing proof that it is a tumor suppressor gene (Rao 
et al., 1996; Shao et al., 1996). Moreover, all ovarian cancers due to BRCAl 
inactivation appear to be malignant epithelial tumors, whereas no evidence was 
found to show the association of BRCAl with borderline tumors or benign cysts, and 
BRCAl-linked ovarian cancers are more likely to be serous than mucinous (Narod, 
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1994). Although the exact function has not been elucidated, recent literatures have 
suggested that both BRCAl and BRCA2 work to preserve chromosome structure, yet 
the precise nature of their contribution has proven difficult to define, because both 
proteins have been implicated in a multitude of different processes including DNA 
repair and recombination, cell cycle control, and transcription (Scully and Livingston, 
2000). BRCAl and BRCA2 proteins also participate in the control of homologous 
recombination and double-strand break repair during cellular response to DNA 
damage. 
Transforming growth factor-P (TGF-P). The TGF-P family of growth 
factors is another tumor suppressor gene family which inhibits proliferation of 
normal epithelial cells (Serra and Moses, 1996). TGF-P causes cell-cycle arrest in Gi 
phase by triggering pathways that result in inhibition of cyclin-dependent kinases. 
Normal ovarian epithelial cells produce, activate, and are growth inhibited by TGF-P 
(Berchuck, 1992), however, most immortalized ovarian cancer cell lines have lost the 
ability to either produce, activate, or respond to TGF-p (Jozan et al., 1992; Zhou and 
Leung, 1992). 
PTEN. PTEN (also termed MMACl, mutated in multiple advanced carcinomas, 
or TEPl, transforming growth factor-P-regulated and epithelial cell-enriched 
phosphatase 1，is discussed as a universal tumor suppressor (Ali et al.，1999). Since 
its discovery in 1997 (Steck et al., 1997; Li et al , 1997), PTEN has been the subject 
of increasing attention in cancer research. PTEN dephosphorylates and consequently 
inactivates protein kinase B (PKB, also known as Akt) (Stambolic et al., 1998; 
Ramaswamy et al., 1999)，a member involved in the intracellular signal transduction 
pathway toward cell survival, lipids dephosphorylation, cell growth stimulation, and 
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apoptosis prevention (Hopkin, 1998). Accordingly, PTEN exhibits a growth-
suppressive effect through both these physiologic functions. Thus, PTEN acts as a 
negative regulator of cell proliferation and Gi progression. However, mutations of 
PTEN gene rarely occur in ovarian cancer. Obata et al. (1998) showed a 
heterogeneous distribution dependent on tumor histology, ranging from 21 percent 
PTEN gene mutations in endometrioid ovarian cancers to 0 percent in those with 
serous or mucinous histology. This reveals that PTEN gene mutation may contribute 
to origin specific ovarian tumorigenesis. 
1.6 Microarray gene expression profiling analysis 
In the past, gene expression was assessed by transcript imaging limited to 
gene-by-gene approaches. Addressing biologic questions in such a reductionist way 
can provide much information on gene structure, function, and regulation. However, 
in response to a cellular perturbation or even during normal resting conditions, gene 
expression changes and evokes hundreds of different gene products while 
suppressing hundreds of other genes. Consequently, scientists have turned their 
attention to methods that enable large-scale studies, through progressively more 
powerful molecular biotechiiiques to satisfy this demand. With the advent of a more 
complete and annotated human genome, technologies such as serial analysis of gene 
expression and DNA microarrays benefit from the Human Genome Project. Those 
technologies supply quantitative information on cell transcriptomes, which cover the 
population of cellular transcripts in a given physiologic or pathologic state. In this 
context, transcriptomics emerged as a new transition in biologic and biomedical 
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research. Transcriptomics is in fact defined as the study of transcriptome dynamics. 
Presently, transcriptome approaches provide clues (1) to understand how cell 
components work together to perform all functions of a given tissue, (2) to pinpoint 
changes in patterns of expression in response to environmental stimuli or 
perturbations, and (3) to gain new insights into human disease basis, stratification, 
and management (causes and consequences of disease, therapeutic outcome, and 
prognosis and diagnosis improvement). 
1.6.1 Principle of DNA microarrays 
The concept of "light-directed, spatially addressable parallel chemical 
synthesis" opened the way for the entire microarrays industry. DNA microarrays are 
microscopic groups of thousands of DNA molecules of known sequences attached to 
a solid surface such as a nylon membrane or a smiple glass microscope slide. Each 
array consists of an orderly organization of samples that provides a medium for 
matching known and unknown samples based on base-pairing rules and automating 
the process of identifying the unknowns. 
DNA microarrays enable broad-scale expression profiling by initially 
preparing labeled ribonucleic probes from genetic material in each sample. It consists 
of microscopic groups of thousands of DNA molecules of known sequences attached 
to a solid surface such as a nylon membrane or a simple glass microscope slide. Each 
array consists of an orderly organization of samples that provides a medium for 
matching known and unknown samples based on base-pairing rules and automating 
the process of identifying the unknowns. In most cases, probes are generated by 
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reverse transcription of total RNA or mRNA. Labeled nucleotides are incorporated 
during this reaction. Other protocols involve either direct RNA labeling with biotin 
or indirect labeling with T7 transcription of double-stranded complementary DNA 
(cDNA) into complementary RNA (cRNA). 
Notably, gene profiling conducted with DNA microarrays can provide the 
relative level of gene expression by calculating the ratio of the experiment and 
control signal intensities. This represents quantitative changes in the expression of 
the corresponding gene in the two compared samples. Generally genes are considered 
as differentially expressed when this ratio is above the arbitrary threshold (often two-
fold), but the levels of significance can be set statistically to lower levels provided 
sufficient replicates are analyzed. A typical experiment often finds differences in 
several hundreds to thousands of genes. Furthermore, the lack of change in highly 
expressed genes can also be valuable informative. Thus the next key step lies in the 
strategy used to deal with the enormous amount of expression data produced by 
microarray measurement. 
The method of signal detection used with DNA chips depends on the type of 
label used in an experiment. Common tagging methods include fluorescent， 
radioactive, and enzymatic approaches. Cy3 and Cy5 are the fluorescent labels 
commonly used. Samples can be contrasted by labeling each pool of probes with a 
fluorochrome of a different color. The same amount of the two probes are then mixed 
together and applied on a single microarray. Depending on the abundance of the 
original mRNA, more or less hybridization will occur on each target nucleic acid 
spotted or directly synthesized on microscope slides or other media. When 
microscope slides are used, an appropriate scanning or imaging reader that provides 
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the fluorescence intensity for Cy3 and Cy5 for each target can reveal the resulting 
hybridization pattern. In the radiolabeling assay, probes prepared from two different 
samples are labeled with phosphorus-32 and separately hybridized on an individual 
array. 
Producing a reliable DNA chip or microarray involves careful control of 
several critical operations. Significant factors include the method of spotting a 
sample onto a membrane or slide, the density of the array, and the application that 
determines the type of material that the spotter places on the substrate. The 
traditional method involves mixing reagents together in a solution and permitting 
diffusion to play a key role in determining how molecules interact. Solid phase 
chemistry, however, enables microarray makers to take advantage of chemical 
bonding to attach a reagent to the soled support. This allows the reagent to be located 
in the specific position on a surface, where it becomes easily identified and 
differentiated from other samples on the same surface. 
The density of an array is determined by the size of the spots, the distance 
between sports, and the support material. The method of printing impacts both the 
spot size and distance between spots. Macroarrays are usually printed on nylon 
membranes about 8 cm by 12 cm in area. They have spots with diameters greater 
than 300 um. These arrays can accommodate up to 5,000 spots. This format is ideal 
for researchers in laboratories that may be operating on a limited budget and do not 
need high throughput applications. However, the diameter of the spots in microarrays 
printed on glass or silicon is typically less than 200 um. Some microarrays offer 
nearly 10,000 spots, while high-density oligonucleotide microarray may have 40,000 
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or more spots on a chip. These cost much expensive significantly but offer higher 
capacity of features profiling. 
1.6.3 Types of micorarray 
cDNA micorarray. Brown's team at Stanford, in collaboration with Mark 
Schena and Ron Davis developed the basic technology for what scientists now regard 
as the traditional type of microarray. It uses lengths of cDNA produced from cellular 
mRNA using the reverse transcriptase polymerase chain reaction (RT-PCR). 
Stretches of cDNA about 500 to 5,000 bases long are immobilized onto a substrate 
and exposed to a set of targets either separately or in a mixture. 
Oligonucleotide microarray. The other form of microarrays consist of 
oligonucleotides or peptide nucleic acids synthesized either in situ on the chip or by 
conventional synthesis followed by immobilization on the chip. The array is exposed 
to labeled sample DNA and hybridized in order to determine the identity and 
abundance of its complementary sequences. The short oligos have strong specificity 
because they can distinguish single base mismatches. This type of microarray is often 
called a DNA chip. 
1.7 Gene expression profiling of ovarian cancer 
In most instances, cancer cells arise as a result of genetic aberrations including 
unregulated, up-regulated or down-regulated, action of receptors, ligands, or 
1 - 2 9 
Gene expression profiling of ovarian caticer Chapter 1. Introduction 
components of signaling pathways. Some examples of the up-regulated and down-
regulated genes identified by microan-ay gene expression profiling in ovarian cancer 
are present in this part. 
1.7.3 Up-regulated genes in ovarian cancer 
SPPl (Wong et al., 2001), HE4, KLKIO, 0SF2 (Matei et al., 2002), hepatocyte 
nuclear factor-1/3 (HNF-l®, and mammaglobin-2 (MGB2) (Adib et al , 2004) are 
potential biomarkers of ovarian cancer recently found by micro array. Platelet-derived 
growth factor (PDGF) and Wnt (Matei et al., 2002) are also found to be up-regulated 
in epithelial ovarian cancer. 
SPPl. SPPl encodes a protein called osteopontin. The niRNA level of SPPl is 
found to be higher in ovarian cancer cell than in normal ovarian epithelial cell (Mok 
et al., 2001). Osteopontin is an acidic glycoprotein contributing to macrophage 
homing and cellular immunity (Weber, 2001). In serous ovarian cancer, a high level 
of osteopontin is localized to the psaniomma bodies, which are laminated calcified 
concretions commonly found in serous cancers. Preoperative osteopontin level is 
significantly higher in women with ovarian cancer compared with those in women 
not having ovarian cancer or those with benign pelvic disease (Kim et al., 2002), 
suggesting osteopontin is a potential biomarker of ovarian cancer. 
HE4. The exact function of the HE4 protein is still not well known. It is, 
however, a member of a family of stable 4-disulfide core proteins that are secreted at 
high level. Studies have shown that the specificity and sensitivity of the HE4 is 
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equivalent to that of the CA125 assay (Hellstrom et al.; 2003). The HE4 assay may 
even have an advantage over the CA125 assay in that it is less frequently positive in 
patients with nonmalignant disease, yet it needs further investigation. 
KLKIO. KLKIO, also known as nonepithelial cell-specific gene 1 (NESl), is a 
secreted serine protease belonging to the large family of kallikrein proteases. It 
encodes the hKlO protein, which is expressed in a variety of normal epithelial cells, 
including breast, ovary, testis, prostate, and small intestine (Shvartsman et al., 2003). 
The physiological function of hKlO has not as yet been elucidated. However, it is 
found that the serum hKlO concentration was significantly elevated in more than half 
of the ovarian cancer patients and such an increase is not observed in serum of 
healthy individuals or in serum of patients with other types of cancer (Luo et al.; 
2001). Meanwhile, seven of the fifteen human KLK genes in the kallikrein family 
were up-regulated in ovarian cancer, they include KLK5, KLK6, KLK7, KLK8, 
KLKIO, KLKll, and KLK14, suggesting that they might share a common mechanism 
or pathway and some of them might also be useful marker (Yousef et al; 2003). 
OSF'2. OSF-2, also know as prostasin, has been shown to overexpress in 
ovarian cancer cell (Mok et al.; 2001). Similar to CA125, prostasin levels were 
frequently elevated in serum from patients with serous epithelial ovarian cancers. A 
lack of correlation between CA125 and prostasin was observed, suggesting 
combination of the use of the two markers could increase the sensitivity. 
HNF-l/S. HNF-l/? (also called variant HNFl, LF-B3, or TCF2), hepatocyte 
nuclear factor-1 beta, is a transcription activatior that regulates the promoters or 
enhancers of genes that are expressed in a liver-specific manner, such as albumin and 
1 - 3 1 
Gene expression profiling of ovarian caticer Chapter 1. Introduction 
^-fetoprotein (Courtois et al., 1988). HNF-1/5 and HNF-la (a protein closely related 
to HNF-1/3) are also thought to be major regulators of glucose homeostatsis 
(Pontoglio, 2000). Reduction of HNF-1/3 by RNA interference (RNAi) caused 
apoptosis (Tsuchiya et al , 2003), suggesting that HNF-ljS expression is essential for 
the survival of clear cell carcinomas cells. HNF-1/3 may also regulate directly or 
indirectly unknown target genes relevant to cell survival. 
MGB2. MGB2, mammaglobin 2, was found to over-express significantly in 
primary and cetastatic ovarian cancers compared to the normal ovarian tissues (Adib 
et al., 2004), and was also over-expressed in endometrioid endometrial carcinomas 
(Moreno-Bueno et al., 2003). MGB2 is a protein initially characterized in rat uterus 
and human endometrium (Muller-Schottle et al., 2000; Becker et al., 1998). It is up-
regulated during the endometrial window of implantation (Kao et al., 2002) and is 
principally involved in glandular secretions in hormone-responsive tissues (Muller-
Schottle et al., 2000). 
Witt. Writ genes encode a family of secreted growth factors critical for 
embryonic pattern formation and cell lineage differentiation (Cadigan and Nusse, 
1997). The Wnt pathway is deregulated in many types of human cancers, including 
ovarian cancer (Palacios et al., 1998; Wu et al., 2001). 
1.7.4 Down-regulated genes in ovarian cancer 
Because a positive result is more reliable when measuring a tumor marker in 
cancer patients, the down-regulated genes found in ovarian caner are less interested 
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than the up-regulated ones in most studies. Therefore the down-regulated genes were 
not well documented as the up-regulated genes. Most of the down-regulated genes 
are tumor suppressor genes. They include ARHI/N0EY2 (Santin et a l , 2004), CAVl 
(Wiechen et al., 2001). PEGS, WISP2 and FHL2 (Adib et al., 2004). 
ARHI/NOEY2. ARHI/NOEY2 is a putative tumor suppressor gene in the Ras 
superfamily that has been mapped to the chromosomal region lp31 (Yu et al., 1999). 
The gene is expressed monoallelically and is imprinted maternally. Loss of 
heterozygosity of the gene is detected in 41 percent of ovarian and breast cancers, 
while the non-imprinted functional allele is deleted in most of cancer samples with 
loss of heterozygosity (Yu et al., 1999). 
CAVL CAVl (caveolin-1) encodes a major component of membrane caveolae 
and an important signaling regulator. It was consistently down-regulated at the level 
of RNA and protein in ovarian carcinomas (Wiechen et al., 2001). In OVCAR-3 
cells that have the CAVl gene suppressed, caveolin-1 overexpression resulted in 
increased apoptosis. Also, anti-sense-mediated suppression of CAVl abrogated the 
sensitivity of bladder carcinoma cells toward apoptotic stimuli (Liu et al., 2001). 
Direct induction of programmed cell death by caveolin-1 has not been described and 
whether this is a cell type-specific effect remains to be investigated. 
PEG3. The human homologue, PEGS, has now been identified and located to 
the homologous chromosome 19ql3.4 with a high degree of conservation seen 
between the human and mouse amino acid sequences of exon 9，although the human 
PEG3 appears to lack the first proline-rich repeat seen in the mouse (Kim et al., 
1997). Highest expression was found in the ovary, testis and placenta by northern 
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blot analysis (Hiby et al., 2001) but the exact cell type within these tissues where the 
gene is expressed has not yet been identified. The imprinted status of human PEGS is 
not well known yet. 
WISP2. This gene encodes a member of the WNTl inducible signaling pathway 
protein subfamily, which belongs to the connective tissue growth factor family. This 
gene may be downstream in the WNTl signaling pathway that is relevant to 
malignant transformation. Its expression in colon tumors is reduced while the other 
two WISP members are overexpressed in colon tumors (Pennica et al., 1998). It is 
expressed at high levels in bone tissue, and may play an important role in modulating 
bone turnover. 
FHL2. FHL (four and one-half LIM domain proteins) proteins consist of four 
LIM domains and a single zinc finger at the NH2 terminus. Since they lack other 
functional or structural domains, they belong to the LIM-only protein family. LIM 
domains are double zinc finger motifs, invoVed in a wide range of protein-protein 
interactions, regulating the function of cytoskeletal proteins, enzymes, or 
transcription factors (Michelsen.et al , 1993; Kosa et al., 1994). FHL2 has been 
shown to promote C2C12 cell differentiation (Martin et al., 2002) and to function as 
a scaffolding protein in mature heart muscle, where it brings together proteins with 
structural and enzymatic properties (Lange et al , 2002). Recently, FHL2 has been 
described as transmitting signals from the cell surface to the nucleus in a Rho-
dependent manner (Miiller et al., 2002), probably due to their binding to integrins or 
other cytoskeletal proteins. 
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1.8 Project aims 
Ovarian cancer，though is not the commonest gynecologic malignancy, is the 
leading cause of cancer death from the female genital tract. The main reason is that 
the disease cannot be detected early and more than half of patients with ovarian 
malignancies present in late stage. By the time the diagnosis is made, tumor cells 
have already spread from the ovary to other abdominal organs and peritoneal 
surfaces. The presence of tumor metastasis make achieving cancer cure much more 
difficult as multiple sites involvement would preclude complete eradication by 
surgical excision or radiotherapy. The currently available chemotherapy though 
potent is not usually capable of achieving cure even in situations where optimal 
surgical debulking has been achieved. Gene therapy, with its potential to 
theoretically reach each cancer cell individually is one of the promising areas of 
research. Identification of genes that are important to tumor cells to establish new 
growth in secondary sites may assist in targeting future therapy. 
The capability of a tumor cell to spread to other sites differentiates a benign 
growth from a malignant tumor. Tumor metastasis does not occur by chance but 
rather only tumor cells with certain characteristics could settle and grow in new sites. 
Previous studies on metastatic genes have usually focused on a few genes at a time 
and their results might not reflect the molecular fingerprint of metastasis as other 
genes that might be involved in the process cannot be evaluated. The use of 
oligonucluotide microarray, a novel high throughput gene expression profiling 
approach, makes it possible to analyze the global pattern of gene expression of a 
tumor. Such expression profiles obtain from tumors might yield insights into the 
specific genetic pathways that are altered during tumorigenesis and metastasis. 
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Therefore, micorarrays should be the preferred method for studying genes chips 
containing thousands of genes of interest, the expression profiles of tumor from 
primary and metastatic sites can be determined and compared. Key and important 
genes conferring metastatic potential can then be identified. The results will be 
verified by studying the genetic profiles of ovarian carcinoma that do not metastasize. 
In this study, we propose to study gene expression profiles in ovarian 
carcinomas with and without metastasis by oligonucleotide micorarray analysis to 
screen for genetic changes that confer tumorigenic and metastastic potential. We 
propose to determine the gene expression profiles in primary site and metastatic sites 
of 4 ovarian carcinomas, and 24 ovarian carcinomas with no apparent metastasis. 
The Affymetrix® oligonucleotide arrays U133A chosen in this study would allow 
the expression profiles of over 22,000 human transcripts to be studied in each tumor 
specimen. The gold of this study include: 1) to determine the gene expression 
profiles of primary and metastatic ovarian cancers, 2) to determine the differences in 
gene expression by comparing the expression profiles between early and advanced 
stage ovarian carcinomas, 3) to determine the differences in gene expression by 
comparing the expression profiles between normal ovary and ovarian carcinomas, 4) 
statistical analysis of results from aims 1, 2 and 3 to identify potential key players 
involved in the tumorigenic and metastatic process. Quantitative real-time PGR is 
also used to further validate the gene expression results. 
The research would provide information in relation to genetic changes that are 
important to ovarian cancer promotion, progression and metastasis. This would 
provide a framework in which further studies could be focused. Identification of 
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genes offers potentials to target cells for gene therapy development that could 
revolutionize the currently unsatisfactory ovarian cancer chemotherapy. 
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CHAPTER 2 MATERIALS AND METHODS 
2.1. Materials 
2.1.1. Patients 
108 patients with ovarian cancer and 19 patients suffering from other 
gynecologic diseases with normal ovaries were recruited from the department of 
Obstetrics and Gynaecology, The Chinese University of Hong Kong, Prince of Wales 
Hospital. Among the 108 ovarian cancer patients, 10 were diagnosed with metastasis 
to lymph nodes or omentum and their metastatic cancer samples were also collected. 
2.1.2 Ovarian tissue specimen 
Ovarian tissues from the 127 patients were collected, we obtained 137 
samples in total (127 ovarian cancers and 10 metastatic cancers of ovary origin). For 
the cases of tumor, a representative part of the tumor tissue was initially dissected. 
Tissues were embedded in optimal condition temperature (OCT) compound for 
frozen section. The histological type and grades of the tumors were classified 
according to the criteria of the WHO. The stage of cancer was established according 
to the FIGO criteria. For the cases of normal ovaries, tissue samples were collected 
from patient suffering from other gynecologic diseases without ovarian abnormality, 
the epithelial part of the ovaries was macro-dissected. The dissected tissues were 
snap-frozen in liquid nitrogen and stored at -70°C pending RNA extraction. 
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2.2 Methods 
In general, cancer tissue and normal ovary specimens were manually dissected 
and their RNAs were extracted with RNeasy Micro Kit (Qiagen, Valencia, CA, 
USA). The RNAs were then used to perform microarray gene expression profiling 
(Affymetrix, CA, USA). After analysis of the expression data, genes of interest were 
selected to perform quantitative real-time PCR validation with ABI PRISM® 
7900HT (Applied biosystems, Foster City, CA, USA). 
2.2.1 Preparation of OCT-embedded Specimen Sections 
The tissue specimens were embedded with OCT compound and snap-frozen 
in liquid nitrogen. Consecutive sections of 20 um were cut from the OCT-embedded 
tissues by cryo-microtome. All the specimen sections were mounted on non-coated 
glass microscopic slides. A section of 5 um was cut after every fifteen consecutive 
sections of 20 um. These sections were mounted on a separate coated glass 
microscopic slide, which were used as a guide for the microdissection of target cells 
from specimen sections. After sectioning, all the sections were fixed in 70% (v/v) 
ethanol at room temperature for 5 minutes. Then the specimen sections were stored 
at - 2 0 � C . 
The guided sections were stained with haemotoxylin and eosin (H & E) 
staining. After staining, the guided sections were dehydrated with an up-graded 
alcohol series, 70%, 80%, 95% and 100% alcohol, each for about 5 minutes. They 
were cleared twice in xylenes for 2 minutes each time and mounted with Histomount. 
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The guided sections were used to corroborate the histological diagnosis and 
determine the location of targets cells in the frozen specimens. 
2.2.2 Microdissection of Tumor Cells from Specimen Sections 
The guided sections were used for locating the target cells during 
microdissection. One frozen specimen section was taken out from freezer for 
microdissection each time. New sterile needles and sterile blades were used to pick 
out the target cells of each case under a dissecting microscope. Approximately 
100,000 tumor cells were microdissected for each tumor sample. Tumor cells were 
then transferred to a 1.5 ml microcentrifuge tube containing 300 ul buffer RLT and 
stored at -70°C. 
2.2.3 Disruption of normal ovarian frozen tissue 
The 19 normal ovarian frozen tissues were disrupted in 300 Buffer RLT 
(Qiagen, Valencia, CA, USA), and stored at -70°C. 
2.2.4 Total RNA Extraction 
To ensure the high quality of RNA, RNeasy Micro Kit (Qiagen, Valencia, CA, 
USA) was used to extract and purify the total RNA from the 139 cases. With the 
RNeasy Micro procedure, all RNA molecules longer than 200 nucleotides are 
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isolated. The procedure enriches mRNA since most RNAs less than 200 nucleotides, 
such as 5.8S rRNA (ribosomal RNA), 5S rRNA, and tRNAs (transfer RNAs), are 
slectively excluded. 
2.2.4.1 RNA Isolation 
For each case, 5 |j.l carrier RNA (4 ng/^il) and 45 |j,l Buffer RLT were added 
to the microdissected cell lysate to a final volume 350 |il. The sample was 
homogenized by vortexing for 30 sec. One volume (350 |a.l) of 70% ethanol was 
added to the homogenized lysate, and the contents were mixed well by pipetting. The 
sample, including any precipitate that has formed, was immediately applied to an 
RNeasy MinElute Spin Column in a 2 ml collection tube. The sample was 
centrifuged for 15 sec at higher than 10,000 rpm, the flow-through was then 
discarded. 350 |liI Buffer RWl (Qiagen, Valencia, CA，USA) was added to the spin 
column and was centrifuged for 15 sec at higher than 10,000 rpm to wash the column. 
The flow-through was discarded. 
2.2.4.2 DNase I Digestion 
10 1^ 1 DNase I stock solution was added to 70 |al Buffer RDD (Qiagen, 
Valencia, CA, USA), and were mixed by gently inverting the tube. The DNase I 
(Qiagen, Valencia, CA, USA) incubation mix (80 |j,l) was pipetted directly onto the 
RNeasy MinElute silica-gel membrane, and was placed at room temperature for 15 
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min in order to digest the DNA contaminant. 350 Buffer RWl was added into the 
spin column, and was centrifuged for 15 sec at higher than 10,000 rpm. The flow-
through and the collection tube were discarded. 
2.2.4.3 RNA Cleanup and Elution 
The RNeasy MinElute Spin Column was transferred into a new 2 ml 
collection tube. 500 fj.1 Buffer RPE was added into the spin column and was 
centrifuged for 15 sec at higher than 10,000 rpm to wash the column. The flow-
through was discarded. 500 |al of 80% ethanol was added to the spin column and was 
centrifuged for 2 min at higher than 10,000 rpm to dry the silica-gel membrane. The 
flow-through and collection tube were discarded. The spin column was transferred 
into a new 2 ml collection tube and was centrifuged at full speed for 5 min with the 
cap opened. The flow-through and collection tube were discarded. The spin column 
was transfer to a new 1.5 ml collection tube. 14 |j,l RNase-free water was added 
directly onto the center of the silica-gel membrane and was centrifuged for 1 min at 
maximum speed to elute the RNA. 
RNA yield was quantified by spectrophotometric analysis using the 
convention that 1 absorbance unit at 260 nm equals 40 ^ig/ml RNA. The absorbance 
was checked at 260 and 280 nm for determination of sample concentration and purity. 
The A260/A280 ratio should be close to 2.0 for pure RNA. Integrity of total RNA 
samples can also be assessed qualitatively on an Agilent 2100 Bioanalyzer. 
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2.2.5 Oligonucleotide Microarray 
28 serous ovarian tumor samples, 10 normal ovary samples and 4 metastatic 
ovarian cancer samples were randomly selected to perform microarray gene 
expression profiling. Of the 28 serous ovarian tumor samples, 8 were in stage I (early 
stage) and 20 were in stage III/IV (advanced stage). No cancer in stage II was 
selected in the experiment. GeneChip® Arrays U133A (Affymetrix, CA，USA) were 
applied. All the reagents and chemicals used in this section were supplied by 
Affymetrix, CA, USA. 
2.2.5.1 Two-Cycle cDNA Synthesis 
As the RNA yield ranged from 300 ng to 5 ^ig, two-cycle cDNA systhesis 
was used, which was used for cDNA synthesis from 10 ng to 100 ng of starting total 
RNA. 
Step 1: First-Cycle, First-Strand cDNA Synthesis 
100 ng total RNA sample was placed into a 0.2 ml PGR tube, 2 i^l of T7-
Oligo(dT) Primer/Poly-A Controls Mix and RlNase-free water were added to a final 
volume of 5 |il. The tube was incubated at 70°C for 6 min. The sample was cooled at 
4°C for 2 min. Master mix prepared from 2 |j,l 5X First-Strand Reaction Mix, 1 \x\ 
O.IM DTT，0.5 III RNase Inhibitor, 0.5 i^l lOmM dNTP and 1 SuperScript II was 
added to the tube. The tube was gently flicked, briefly centrifuged and then 
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immediately incubated at 42°C for 1 hour. The sample was heated at 70°C for 10 min 
to inactivate the RT enzyme, and then cooled at 4°C for 2 min. 
Step 2: First-Cycle, Second-Strand cDNA Synthesis 
4.8 |al RNase-free water, 4 |al freshly diluted MgClz (17.5mM), 0.4 [i\ dNTP 
(10 mM), 0.6 ]i\ E, coli DNA Polymerase I and 0.2 RNase H were added to the 
sample from step 1 reaction. The tube was incubated at 16°C for 2 hours, 75°C for 10 
min and cooled at 4 °C for 2 min. 
Step 3: First-Cycle, in-vitro transcription (IVT) Amplification of cRNA 
Master mix prepared from 5 },il lOX Reaction Buffer, 5 i^l ATP Solution, 5 i^l 
CTP Solution, 5 fil UTP Solution, 5 GTP Solution and 55 Enzyme Mix was 
added to the cDNA sample from step 2. The tube was incubated at 37°C for 16 hour. 
Step 4: First-Cycle, Cleanup of cRNA 
50 [i\ of RNase-free water and 350 i^l IVT cRNA Binding Buffer were added 
to the rVT reaction product. 250 ethanol (96-100%) was added to the lysate, and 
was mixed well by pipetting. The sample in 700 |j,l total volume was applied to the 
IVT cRNA Cleanup Spin Column for cRNA cleanup. 13 i^l of RNase-free Water was 
used to eluted the cRNA and resulted in 11 i^l elute volume. RNA yield was 
determined by measuring the absorbance at 260 nm. 
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Step 5: Second-Cycley First-Strand cDNA Synthesis 
600 ng of cRNA from step 4 was mixed with 2 |al freshly diluted random 
primers (0.2 }j.g/|il). The mixture was incubated at 70°C for 10 min, cooled at 4°C for 
2 min. Master mix prepared from 4 }j.l 5X First-Strand Reaction Mix, 2 |a.l 0.1 M 
DTT, 1 |il RNase Inhibitor, 1 i^l dNTP (10 mM) and 1 fil SuperScript II were added 
to the cRNA/random primer sample. The tube was incubated at 42 °C for 1 hour, and 
then cooled at 4°C for 2 min. 1 |j,l of RNase H was added to the sample for a final 
volume of 21 |j1 The sample was heated at 95°C for 5 min, and then cooled at 4°C 
for 2 min. 
Step 6: Second-Cycle^ Second-Strand cDNA Synthesis 
4 ]i\ of freshly diluted T7-01igo(dT) Primer (5 |a,M) was added to the sample 
from step 5 for a final volume of 25 |li1. The tube was incubated at 70°C for 6 min, 
and then cooled at 4°C for 2 min. Master mix prepared from 88 RNase-free Water, 
30 1^1 5X Second-Strand Reaction Mix, 3 |al dNTP (10 mM) and 4 |li1 E. coli DNA 
Polymerase I was added to the sample. The tube was incubated at 16°C for 2 hours. 2 
|j,l of T4 DNA Polymerase was added to the sample for a final volume of 152 The 
tube was incubated at 16°C for 10 min, and then cooled at 4°C for 2 min. 
Step 7: Cleanup of Double-Stranded cDNA 
600 |al of cDNA Binding Buffer was added to the double-strand cDNA 
synthesis preparation. Yellow mixture was obtained. 500 of the sample was 
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applied to the cDNA Cleanup Spin Column sitting in a 2 ml Collection Tube for 
cleaning up the cDNA. 14 |j,l of cDNA Elution Buffer was used for elution and 
resulted in 12 fj.1 eluate volume. 
2.2.5.2 Synthesis of Biotin-Labeled cRNA 
12 III of template cDNA from the above step, 4 \x\ lOX IVT Labeling Buffer, 
12 IVT Labeling NTP Mix and 4 |il IVT Labeling Enzyme Mix were mixed 
together for a final volume 40 \xl The tube was incubated at 37 °C for 16 hours 
To purify the cRNA synthesized, 60 i^l of RNase-free Water and 350 |j,l IVT 
cRNA Binding Buffer were added to the sample. 250 ethanol (96-100%, v/v) was 
added to the lysate and mixed well by pipetting. The sample in total volume 700 
was applied to the IVT cRNA Cleanup Spin Column for cRNA cleanup. 10 }il of 
RNase-free Water was used to elute the cRNA. 
The concentration and purity of the cRNA was determined by 
spectrophotometric analysis at absorbance 260 nm and 280 nm. The yield and size 
distribution of labeled transcripts were estimated by Agilent 2100 Bioanalyzer. 
2.2.5.3 Fragmenting the cRNA for Target Preparation 
8ul of 5X Fragmentation Buffer was added to 20 fig cRNA, RNase-free 
Water was added for a final volume 40 The tube was incubated at 94°C for 35 
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min and followed by putting on ice. The undiluted, fragmented cRNA was stored at -
20°C pending hybridization. The distribution of RNA fragment sizes was analyzed 
by Agilent 2100 Bioanalyzer. The fragment sizes were approximately 35 to 200 
bases. 
2.2.5.4 Target Hybridization 
Hybridization Cocktail for single probe array was prepared from 15 )j,g 
fragmented cRNA, 5 |j,l Control Oligonucleotide B2 (3 nM), 15 20X Eukaryotic 
Hybridization Controls, 3 |il Herring Sperm DNA (10 mg/ml), 3 i^l BSA (50 mg/ml), 
150 |j.l DMSO, and water was added to final volume 300 |li1. The hybridization 
cocktail was heated to 99°C for 5 min and followed by 45°C for 5 min in a heat 
block. The hybridization cocktail was spinned at maximum speed for 5 min to 
remove any insoluble material. The probe array was equilibrated to room 
temperature immediately before use. The array was wet by filling with 200 [li of IX 
Hybridization Buffer and incubated at 45°C for 10 min with rotation. The buffer 
solution was removed from the probe array, the array was then filled with 200 |j,l of 
the clarified hybridization cocktail. The probe array was placed into Hybridization 
Oven at 45°C with rotation at 60 rpm for 16 hours. 
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2.2.5.5 Array Washing, Staining, and Scanning 
Streptavidin Phycoerythrin (SAFE) Stain Solution for one probe array was 
prepared from 600 i^l 2X Stain Buffer (200 mM MES，2 M [Na+]，0.1% Tween-20), 
48 |al BSA (50 mg/ml), 12 |il SAFE (1 mg/ml) and 540 fil de-ionized water. 
Antibody Solution Mix for one probe array was prepared from 300 |lx1 2X Stain 
Buffer, 24 |li1 BSA (50 mg/ml), 6 |al Goat IgG Stock (10 mg/ml in 150 mM NaCl), 
3.6 |j.l biotinylated antibody (0.5 mg/ml) and 266.4 |j,l de-ionized water. 
The probe array was washed with Non-Stringent Wash Buffer (6X SSPE, 
0.01% Tween-20) at 25°C for 10 cycles, followed with Stringent Wash Buffer (100 
mM MES, 0.1 M [Na+]，0.01% Tween-20) at 50°C for 4 cycles. The array was 
stained in SAFE solution at 25°C for 10 min, and then washed with Non-Stringent 
Wash Buffer at 25°C for 10 cycles. The array was second stained in antibody 
solution at 25°C for 10 min, and followed in SAFE solution at 25°C for 10 min. The 
array was then washed with Non-Stringent Wash Buffer at 30°C for 15 cycles. 
The probe array was scanned after the wash protocols were complete. The 
scanner was controlled by Affymetrix® Micorarray Suite (MAS). 
2.2.5.6 Statistical Analysis of Microarray Data 
After raw image DAT data files were initially processed to create CEL files, 
DNA-Chip Analyzer (dChip) version 1.3 software package (www.dCHIP.org) (Li 
and Wong, 2001a, b) was used for data quality checking and high-level analysis. The 
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raw expression signals were normalized and the model-based expression indexes for 
each probe set were computed. Unsupervised gene selection was performed to select 
genes with large variation using the criteria: (1) variation across samples (standard 
deviation / mean) between 1.2 and 10; (2) present call percentage in the array higher 
than 20 percent. Unsupervised Hierarchical clustering was performed to see whether 
samples in the same clinical variable would be clustered together. Supervised gene 
selection was done to select genes with the fold change larger than the threshold 
cutoff value between the two compared groups. 
While comparing cancer and normal samples, criteria were set at: (1) 90% 
lower bound fold change larger than 4; (2) p-value for t-test of significant difference 
between compared groups less than 0.01. False discovery rate (FDR) was assessed 
by 100 permutations. 
While comparing advanced and early stage tumor samples, criteria were set at 
(1) 90% lower bound fold change larger than 2; (2) p-value for t-test of significant 
difference between compared groups less than 0.01. FDR was assessed by 100 
permutations. 
While comparing paired metastasis and primary cancer samples, criteria were 
set at: (1) 90% lower bound fold change larger than 1.5; (2) p-value for paired t-test 
of significant difference between compared groups less than 0.05 FDR was assessed 
by 100 permutations. 
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2.2.6 Quantitative Real-time Polymerase Chain Reaction 
After statistical analysis, 23 genes of most interest from the three 
comparisons were selected. 
2.2.6.1 Primer and Probe 
Primers and probes sequences for the 23 selected genes were purchased from 
Applied Biosystem (Foster City, CA, USA). 
2.2.6.2 Reverse-transcription 
The RNA of the 137 cases and the Human Universal Reference Total RNA 
(BD Biosciences Clontech, Palo Alto, CA, USA) was reverse-transcripted into the 
first-strand cDNA by SuperScript™ II RNase H— reverse transcriptase (Invitrogen 
Life Technology, Carlsbad, CA, USA). For each case, 250 ng random primers, 3-5 
|ig total RNA, 1 |Lil 10 mM dNTP Mix (Invitrogen Life Technology, Carlsbad, CA, 
USA) and sterile, distilled water were added to a microcentrifuge tube to a final 
volume 12 ^il. The mixture was heated to 65°C for 5 min and quick chilled on ice. 
The contents of the tube were collected by brief centrifugation. 4 i^l 5X First-strand 
Buffer, 2 0.1 M DTT and Ijil RNaseOUT™ Recombinant Ribonuclease Inhibitor 
(40 units/|j.l) (Invitrogen Life Technology, Carlsbad, CA, USA) were then added to 
the mixture. The contents were mixed gently and incubated at 25°C for 2 min. 1 |li1 
200 units/|al SuperScript™ II RT was added, the contents were mixed by pipetting 
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gently up and down. The mixture was incubated at 25°C for 10 min, 42°C for 50 min, 
and followed by reaction inactivation at 70°C for 15 min. 
2.2.6.3 Plate Setup 
Serial dilution of cDNA sample prepared from the Human Universal 
Reference Total RNA (BD Biosciences Clontech，Palo Alto, CA, USA) was used to 
construct standard curves for the candidate genes and the GAPDH amplifications. 
The unknown samples were cDNA prepared from total RNA isolated from the 139 
ovarian cases. All the samples were duplicated in the setup. 
2.2.6.4 Fluocogenic PCR 
The total 137 cases were subjected to the fluorogenic 5'-exonuclease assay 
for the 23 selected genes and GAPDH. The amplification was performed in 5 |j.l final 
reaction volume containing 2X TaqMan® Universal PCR Master Mix (Applied 
Biosystems, Foster City, CA, USA), optimized concentration of the primer and probe 
of selected gene. All the reactions were performed in 384-well optical reaction plate 
that was covered by ABI PRISM® optical adhesive cover designed for ABI 
PRISM® 7900HT Sequence Detection System. The thermal cycling conditions were 
2 min at 50°C, 10 min at 95°C followed by 45 cycles of 15 sec at 95°C, 1 min at 
60°C. The fluorescence collected by the 7900HT system was interpreted by SDS2.1 
software (Applied biosystems, Foster City, CA, USA). The fluorescence from 
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GAPDH was used as a endogenous reference control to normalize the fluorescent 
signal of the target genes. 
2.2,6,5 Statistical Analysis of Quantitative Real-time PCR Data 
The fold changes of the target genes were determined by Relative Standard 
Curve Method. For each experimental sample, the amount of target and 
Glyseraldehyde-3-phosphate dehydrogenase (GAPDH) was determined from the 
appropriate standard curve. Then, the target amount is divided by the GAPDH 
amount to obtain a normalized target value. The normalized amount of target of the 
experimental group was compared to the control group of the samples to obtain the 
expression fold change. 
Statistical analysis of significant difference among experimental samples and 
control samples was tested by Mann-Whitney Rank Test at 95% confidence interval 
The Pearson product-moment correlation was used to evaluate the correlation of the 
expression level of candidate genes of microarray and real-time polymerase chain 
reaction (PCR) expression at 95% confidence interval. For those candidate genes 
showing significant (p < 0.05 from Mann-Whitney Rank Test) fold change in the 
ovarian tumor of non-serous epithelial type, the significant difference of expression 
of candidate genes between different histological types of ovarian tumor was 
estimated by Kruskal-Wallis Test and Mann-Whitney Rank Test at 95% confidence 
interval. 
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CHAPTER 3 RESULTS 
3.1 Microarray gene expression data analysis 
3.1.1 Unsupervised Gene Selection 
689 of 22283 probe sets satisfied the filtering criteria: (1) Variation across 
samples (standard deviation / mean) between 1.2 and 10; (2) Present call percentage 
in the array more than 20%. Figure 3.1 shows the unsupervised Hierarchical 
clustering graph (p-value for gene clustering < 0.001，p-value for sample clustering 
< 0.01). Normal and tumor samples were separated well. It revealed that majority of 
these genes might be mainly driven by normal-tumor difference. The clustering 
picture clearly shows that there is a cluster of genes up-regulated in normal ovary 
compared with tumor samples. Within tumor samples, however, the different clinical 
variables do not seem to be separated very well. The tumor samples with 
pathological grading 1 grouped together, there might be some genes separating 
grade 1 and grade 2 or 3 tumor samples. Moreover, the metastatic cancer samples 
grouped together with their paired primary cancer samples, it might be because the 
gene expression profiles are similar in the metastatic and primary cancer samples 
except some genes are differentially expressed. 
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Figure 3.1 Hierarchical clustering (p-value for gene clustering < 0.001, p-value for 
sample clustering < 0.01) picture of unsupervised gene selection using the criteria: 
1) Variation across samples: 1.2 < Standard deviation / Mean < 10; 2) Present call % 
in the array used >= 20 %. Red represents the up-regulated probe sets while blue 
represents the down-regulated probe sets. 
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3.1.2 Supervised Gene Selection 
3.1.2.1 Gene expression profiles distinguish Serous Epithelial Ovarian Tumor 
from Normal Ovary and identify differentially expressed genes 
Using (1) lower bound fold change larger than 4; 2) p-value for t-test less than 
0.01 to compare tumor and normal samples, 449 probe sets representing 392 genes 
were obtained with 0 % median false discovery rate (FDR) by 100 permutations. 
Among the 392 genes, 224 were up-regulated and 168 were down-regulated in 
ovarian cancers. Table 3.1 shows the output gene list. Table 3.2 shows the genes 
found previously by other groups that were differentially regulated in epithelial 
serous ovarian cancer overlapped with our gene list, there are 27 genes in total. 
Figure 3.2 shows the hierarchical clustering (p-value < 0.001) picture of the 
differentially expressed genes. The normal and tumor samples separate well, the 
normal arrays behave very consistently across different samples. Annotation 
classification (p-value < 0.001) accessed by gene ontology (GO) of the differentially 
expressed genes is shown in Figure 3.3. In the category of molecular function, it 
showed that the genes are involved in trypsin activity (46 %), chymotrypson activity 
(36 %) and tissue kallidrein (18 %). In the category of biological process, the 
majority of genes are involved in development (27 %), organogenesis (16 %), 
oncogenesis (11 %) and cell adhesion (11 %), the remaining include mitotic cell 
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cycle (8 %), M phase (6 %), mitosis (6 %), histogenesis (4 %), neuropeptide 
signaling pathway (3 %), ectoderm development (3 %), epidermal differentiation (3 
%), and regulation of mitosis (2 %). In the category of cellular component, the 
majority of genes are involved in extracellular (54 %) and extracellular matrix (22 
%), the remaining include intermediated filament (8 %), spindle (8 %) and 
intermediate filament cytoskeleton (8 %). 
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Table 3.1 List of differentially regulated (fold change > 4; p-value < 0.01) genes in 
Serous Epithelial Ovarian Tumor compared to Normal Ovary. 
Gene Fold 
Accession Gcnie name symbol Chromosome change 
L33930 CD24 antigen (small cell lung carcinoma cluster 4 antigen) CD24 6q21 1807.87 
AW517716 ESTs, Moderately similar to cytokine receptor-like factor — — 1338.09 
2; cytokine receptor CRL2 precusor [Homo sapiens] 
[H.sapiens] 
X83425 Lutheran blood group (Auberger b antigen included) LU 19ql3.2 1254.2 
NM_024690.1 mucin 16 MUC16 19ql3.2 1156.6 
NM_016725.1 folate receptor 1 (adult) FOLRl Ilql3.3-ql4.1 1150.74 
NM_002407.1 secretoglobin, family 2A, member 1 SCGB2A1 l l q l 3 1139.21 
BC002700.1 keratin 7 KRT7 12ql2-ql3 801.55 
AJ242547.1 mucin 4, tracheobronchial MUC4 3q29 724.54 
NM_000096.1 ceruloplasmin (ferroxidase) CP 3q23-q25 637.77 
AI422335 paraneoplastic antigen HUMPPA 17q25.1 523.71 
Z19i74 keratin 17 KRT17 17cjl2-q21 508.89 
NM_006551.2 secretoglobin, family 1D, member2 SCGB1D2 l l q l 3 450.89 
NM_001306.1 claudin 3 CLDN3 7q 11.23 415.97 
NM_005733.1 kinesin family member 20A KIF20A 5q31 414.07 
NM_001255.1 CDC20 cell division cycle 20 homolog (S. cerevisiae) CDC20 lp34.1 375.65 
NM_001038.丨 sodium channel, nonvoltage-gated 丨 alpha SCNNIA 12pl3 353.62 
A J 0 n 7 1 2 troponin Tl, skeletal, slow TNNTl 19ql3.4 341.41 
AA541630 runt-related transcription factor 3 RUNX3 lp36 338.13 
J02871.1 cytochrome P450’ family 4, subfamily B, polypeptide 丨 CYP4B1 Ip34-pl2 333.11 
NM_016425.1 transmembrane protease, serine 4 TMPRSS4 llq23.3 320.86 
NM_015366.1 Rho GTPase activating protein 8 ARHGAP8 22ql3.31 297.06 
NM_001692.1 ATPase, 11+ transporting, lysosomal 56/58kDa, VI subunit ATP6V1B1 2pl3.1 295.6 
B, isoform 1 (Renal tubular acidosis with deafness) 
NM_001305.1 claudin 4 CLDN4 7ql l .23 294.67 
NM_003710.1 serine protease inhibitor, Kunitz type 1 SPINTI 15ql5.1 285.91 
NM_015515.1 keratin 23 (histone deacetylase inducible) KRT23 17q21.2 274.19 
A1653981 LI cell adhesion molecule (hydrocephalus, stenosis of LICAM Xq28 266.28 
aqueduct of Sylvius 1，MAS A (mental retardation, aphasia, 
shuffling gait and adductcd thumbs) syndrome, spastic 
paraplegia 1) 
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U20428.1 suppression of tumorigenicity 14 (colon carcinoma, ST14 1 Iq24-q25 239.49 
matriptase, epithin) 
NM_018131.1 chromosome 10 open reading frame 3 ClOorD 10q23.33 224.43 
NM_005978.2 SI 00 calcium binding protein A2 S100A2 lq21 223.3 
NM_020995.1 haptoglobin-related protein HPR 16q22.1 220.93 
NM_006342.1 transforming, acidic coiled-coil containing protein 3 TACC3 4pl6.3 216.06 
NM一000142.2 fibroblast growth factor receptor 3 (achondroplasia, FGFR3 4pl6.3 214.22 
thanatophoric dwarfism) 
NM一003862.1 fibroblast growth factor 18 FGF18 5q34 194.98 
NM_002309.2 leukemia inhibitory factor (cholinergic differentiation LIF 22ql2.2 194.77 
factor) 
NM_024053.1 chromosome 22 open reading frame 18 C22orfl8 22ql3.2 193.97 
NM_000424.1 keratin 5 (epidermolysis bullosa simplex, KRT5 12ql2-ql3 193.48 
Dowling-Meara/Kobner/Weber-Cockayne types) 
NM_0I4178.1 syntaxin binding protein 6 (amisyn) STXBP6 14ql2 185.14 
AI561253 hypothetical protein LOC339692 LOC339692 2ql3 180.36 
AU160004 IGF-II mRNA-binding protein 3 IMP-3 7p l l 176.26 
AF177272.1 UDP glycosyltransferase 2 family, polypeptide B28 /// UDP UGT2B28 4ql3.2 170.21 
glycosyltransferase 2 family, polypeptide B28 
AI610869 Mucin 1, transmembrane MUCl lq21 167.2 
AF083389.丨 Wolf-Hirschhom syndrome candidate 1 WHSCl 4pl6.3 153 
NM_002160.1 tenascin C (hexabrachion) TNC 9q33 142.27 
NM_018658.1 potassium inwardly-rectifying channel, subfamily J, member KCNJ16 17q23.1-q24.2 136.53 
16 
NM_001168.1 baculoviral lAP repeat-containing 5 ( urviving) BIRC5 17q25 134.38 
NM_014398.1 lysosomal-associated membrane protein 3 LAMP3 3q26.3-q27 131.89 
BE542323 vestigial like 1 (Drosophila) VGLLl Xq26.3 115.73 
U71207.1 eyes absent homolog 2 (Drosophila) EYA2 20ql3.1 110.5 
AW769732 paired box gene 2 PAX2 10q24 108.65 
NM_002670.1 plastin 1 (I isoform) PLSl 3q23 102.86 
AL524520 leucinc-rich repeal-containing G protein-coupled receptor 5 LGR5 12q22-q23 98.63 
NM_005564.1 lipocalin 2 (oncogene 24p3) LCN2 9q34 86.49 
M80927.1 chilinase 3-like 1 (cartilage glycoprotein-39) CHI3L1 lq32.1 68.12 
NM_004636,1 senia domain, immunoglobulin domain (Ig), short basic SEMA3B 3p21.3 67.14 
domain, secreted, ( emaphoring) 3B 
BE305165 protein phosphatase 1, regulatory (inhibitor) subunit I4B PPP1R14B 1 l q l 3 58.29 
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J04152 tumor-associated calcium signal transducer 2 TACSTD2 Ip32-p31 58.05 
AI862445 tumor necrosis factor, alpha-induced protein 2 TNFAIP2 14q32 55.66 
BG170541 met proto-oncogene (hepatocyte growth factor receptor) MET 7q31 46.78 
NM_001067.1 topoisomerase (DNA) II alpha 170kDa T0P2A 17q21-q22 45.86 
NM_003064.1 secretory leukocyte protease inhibitor (antileukoproteinase) SLPI 20ql2 45 
AL567376 LY6/PLAUR domain containing 1 LYPDCl 2q21.2 39.29 
U73945.1 defcnsin’ beta 丨 DEFBl 8p23.2-p23.1 39.15 
NM_003914.1 cyclin Al CCNAl 13ql2.3-ql3 37.64 
NM_005823.2 mesothelin MSLN 16pl3.3 34.67 
NM_001048.1 somatostatin SST 3q28 34.48 
U76549.1 keratin 8 III keratin 8 KRT8 12ql3 34.06 
NM_002354.1 tumor-associated calcium signal transducer 1 TACSTDl 2p21 33.95 
NM_002497.1 NIMA (never in mitosis gene a)-related kinase 2 NEK2 Iq32.2-q41 33.45 
NM_004362.1 calmegin CLGN 4q28.3-q31.1 30.02 
AK024840,1 block of proliferation 1 BOPl 8q24.3 29.74 
NM_017697.1 hypothetical protein FLI20171 FU20171 8q22.1 29.1 
NM_001584.1 chromosome 11 open reading frame 8 Cl lorfS l l p l 3 28.24 
NM_002423.2 matrix metalloproteinase 7 (matrilysin, uterine) MMP7 Ilq21-q22 28.24 
AW000928 neuronal PAS domain protein 2 NPAS2 2 q l l . 2 27.37 
NM—003986.1 butyrobetaine (gamma), 2-oxoglutarate dioxygenase BBOXl 1 lp l4 .2 26.32 
(gamnia-butyrobetaine hydroxylase) 1 
NM_000346.1 SRY (sex determining region Y)-box 9 (campomelic S 0 X 9 17q24.3-q25.1 25.91 
dysplasia, autosomal sex-reversal) 
NM_018952.1 homeo box B6 H 0 X B 6 17q21.3 25.44 
NM_014736.1 KlAAOlOl KlAAOlOl 15q22.31 25.4 
NM一002145.1 homeo box B2 H 0 X B 2 17q21-q22 25.35 
NM_018454.1 nucleolar and spindle associated protein 1 NUSAPl 15ql5.1 24.92 
NM_000224.1 keratin 18 KRT18 12ql3 24.74 
NM—024508.1 zinc finger, BED domain containing 2 ZBED2 3ql3.13 24.56 
NM_016929.1 chloride intracellular channel 5 CLIC5 6pl2.1-21.1 24.04 
NM_001710.1 B-factor, properdin BF 6p21.3 23.93 
NM_006681.1 neuromedin U NMU 4 q l 2 23.69 
NM_024889.1 chromosome 10 open reading frame 81 ClOorfSl 10q25.3 22.54 
NM_005562.1 laminin, gamma 2 LAMC2 Iq25-q31 22.2 
NM_001338.1 coxsackie virus and adenovirus receptor CXADR 21q21.1 21.34 
BE465829 — — … 20.71 
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AFOl7307.1 E74-like factor 3 (ets domain transcription factor, ELF3 lq32.2 20.54 
epithelial-specific) 
NM_006103.1 WAP four-disulllde core domain 2 WFDC2 20ql2-ql3.2 20.49 
AI671049 cyclin El CCNEl 19ql2 19.78 
AI219073 epidermal growth factor receptor pathway substrate EPS8L1 19q 13.42 19.24 
8-reIated protein 1 
NM_006853.1 kallikrein 11 KLKll 19ql 3.3-ql3.4 18.38 
NM_005498.2 adaptor-related protein complex 1, mu 2 subunit AP1M2 19pl3.2 18.14 
NM_023930.1 potassium channel tetramerisation domain containing 14 KCTD14 1 IqM.l 17.95 
NM_020672.1 S100 calcium binding protein A14 S100A14 lq21.3 17.87 
AF298547.1 NACHT, leucine rich repeat and PYD containing 2 NALP2 19ql3.42 17.69 
AK021918.1 G protein-coupled receptor 172A GPR172A 8q24.3 17.41 
NM_018245.1 oxoglutarate dehydrogenase-Iike OGDHL lOq 11.23 17.12 
AB002155.1 uroplakin IB UPKIB 3ql3.3-q21 17.11 
M83248.1 secreted phosphoprolein 1 (osteopontin, bone sialoprotein I, SPPl 4q21-q25 17.1 
early T-lymphocyte activation 1) 
NM_007196.1 kallikrein 8 (neuropsin/ovasin) KLK8 19ql3.3-ql3.4 16.89 
NM._001034.1 ribonucleotide reductase M2 polypeptide RRM2 2p25-p24 16.37 
AA554945 Pyruvate kinase, muscle PKM2 15q22 15.44 
NM_018265.1 hypothetical protein FU10901 FU10901 lq32.1 15.34 
NM_000227.1 laminin, alpha 3 LAMA3 18qll .2 14.83 
NM_024022.1 transmembrane protease, serine 3 TMPRSS3 21q22.3 14.61 
NM_018492.1 PDZ binding kinase PBK 8p21.2 14.54 
NM_020639.1 ankyrin repeat domain 3 R1PK4 21q22.3 14.5 
AI264306 adrenergic, alpha-2C-, receptor ADRA2C 4pl6 14.46 
BCOOl060.1 paired box gene 8 PAX8 2ql2-ql4 14.38 
U94592.1 uncoupling protein 2 (mitochondrial, proton canier) UCP2 1 l q l 3 14.37 
AF275945.1 epithelial V-like antigen 丨 EVAl l lq24 13.79 
AF047760.1 phosphatidic acid phosphatase type 2C PPAP2C 19pl3 13.79 
BE974098 tumor protein D52 TPD52 8q21 13.7 
NM_000077.1 cyclin-dependent kinase inhibitor 2A (melanoma, pi6, CDKN2A 9p21 13.63 
inhibits CDK4) 
NM-004415.1 desmoplakin (DPI, DPIl) DSP 6p24 13.63 
NM_005764.1 epithelial protein up-regulated in carcinoma, membrane MAP17 lp33 13.38 
associated protein 17 
NM_015925.1 liver-specific bHLH-Zip transcription factor LISCH7 19ql3.12 13.33 
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NM_004360.1 cadherin 1，type 1’ E-cadherin (epithelial) CDHl 16q22.丨 13.27 
NM_005143.1 haptoglobin HP 16q22.1 13.24 
AL554008 G protein-coupled receptor 56 GPR56 GPR56 13.12 
NM_006984.1 claiidin 10 CLDNIO 13q31-q34 12.76 
AF088867.1 anterior gradient 2 lioniolog (Xenepus laevis) AGR2 7p21.3 12.69 
NM_022346.1 chromosome condensation protein G HCAP-G 4pl5 .33 12.67 
NM_005196.1 centromere protein F, 350/400ka (mitosin) CENPF Iq32-q41 12.32 
NM_005132.1 REC8-like 1 (yeast) REC8L1 14ql l .2 -q l2 12.18 
AF146796.1 solute carrier family 34 (sodium phosphate), member 2 SLC34A2 4pl5.3-pl5.1 12.16 
NM_012310.2 kinesin family member 4A KIF4A Xql3.1 12.1 
NM一018123.1 asp (abnormal spindle)-like, microcephaly associated ASPM lq31 11.94 
(Drosophila) 
AL031588 cadherin, EGF LAG seven-pass G-type receptor 1 (flamingo CELSRl 22ql3.3 11.84 
homolog, Drosophila) 
NM_006I01.1 highly expressed in cancer, rich in leucine heptad repeats KNTC2 18pl l .32 11.58 
NM_024626.1 immune costimulatory protein B7-H4 B7-H4 lpl3.1 11.3 
NM_014750.1 discs, large homolog 7 (Drosophila) DLG7 DLG7 11.25 
NM_003318.1 TTK protein kinase TTK 6ql3-q21 11.02 
AL050025.1 carbonic anhydrase XII CA12 15q22 10.66 
AB020676.1 KIBRA protein KIBRA 5q34 10.61 
T62571 microtubule-associated protein 7 MAP7 6q23.3 10.55 
ABO 11446.1 aurora kinase B AURKB 17pl3.1 10.48 
NM_025080.1 asparaginase like 1 ASRGLl l l q l 2 . 3 10.36 
NM_017522.1 low density lipoprotein receptor-related protein 8, LRP8 lp34 10.29 
apolipoprotein e receptor 
NM_015507.2 EGF-like-domain, multiple 6 EGFL6 Xp22 10.23 
NM_006115.1 preferentially expressed antigen in melanoma FRAME 2 2 q l l . 2 2 9.91 
AI762627 protein tyrosine phosphatase, receptor type, F PTPRF lp34 9.91 
NM_022454.1 SRY (sex determining region Y)-box 17 SOX 17 8q 11.23 9.91 
Z48199 syndecan 1 SDCl 2p24.1 9.67 
BE466525 ecotropic viral integration site 1 EVIl 3q24-q28 9.65 
NM_012338.1 transmembrane 4 superfaniily member 12 TM4SF12 7q31.31 9.58 
AW772192 V-erb-a erythroblastic leukemia viral oncogene homolog 4 ERBB4 2q33.3-q34 9.56 
(avian) 
NM 一 0 0 6 0 1 7 . 1 prominin 1 PROMl 4pl5 .32 9.55 
NM_004038.1 amylase, alpha lA; salivary A M Y I A lp21 9.44 
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NM_000962.1 prostaglandin-endoperoxide synthase 1 (prostaglandin G/H PTGSl 9q32-q33.3 9.28 
synthase and cyclooxygenase) 
NM_001211.2 BUBl budding uninhibited by benzimidazoles 1 homolog BUBIB 15ql5 9.08 
beta (yeast) 
NM一001311.1 cysteine-rich protein 1 (intestinal) CRIPl 14q32.33 8.99 
AI653169 adenylate kinase 3 AK3 9pter-pl3|lp31.3/// 8.97 
12pl l .22 
NM_012485.1 hyaluronan-mediated motility receptor (RHAMM) HMMR 5q33.2-qter 8.95 
NM_004701.2 cyclin B2 CCNB2 15q22.2 8.93 
NM_000694.1 aldehyde dehydrogenase 3 family, member B1 ALDH3B1 l l q l 3 8.89 
BF344237 … --- … 8.75 
NM_001071.1 thymidylate synthetase TYMS 18pll .32 8.67 
NM_013238.1 DNAJ domain-containing DNAJDl DNAJDl 8.56 
Ml 9720 — — — 8.46 
BC001451.1 testis derived transcript (3 LIM domains) TES 7q31.2 8.35 
NM一020387.1 RAB25, member RAS oncogene family RAB25 lq22 8.34 
NM_006398.1 ubiquitin D UBD 6p21.3 8.31 
NM_019027.1 RNA-binding protein FU20273 4p l3-p l2 8.27 
BC001051.1 ADP-ribosylation factor-like 7 ARL7 2q37.1 8.21 
NM_001982.1 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 ERBB3 12ql3 8.07 
NM_002193.1 inhibit!, beta B (activin AB beta polypeptide) INHBB 2cen-ql3 8 
AI935123 chromosome 14 open reading frame 78 C14orf78 14q32.33 7.97 
NM_001949.2 E2F transcription factor 3 E2F3 6p22 7.9 
AA886335 calmodulin-like 4 CALML4 15q23 7.82 
NM_005046.1 kallikrein 7 (chymotryptic, stratum comeum) KLK7 19ql3.41 7.82 
NM_017949.1 chromosome 14 open reading frame 34 CUEDCl 17q23.2 7.81 
AK021586.丨 agrin AGRN lp36.33 7.7 
NM_001878.2 cellular retinoic acid binding protein 2 CRABP2 lq21.3 7.7 
AL324035 cell division cycle 2, Gl to S and G2 to M CDC2 10q21.1 7.69 
NM_002131.1 high mobility group AT-hook 丨 HMGAl 6p21 7.65 
AI867102 nucleoporin 210kDa NUP210 3p25.2-p25.1 7.51 
NM_002606.1 phosphodiesterase 9A PDE9A 21q22.3 7.49 
NM_005756.1 G protein-coupled receptor 64 GPR64 GPR64 7.48 
AFl 54005.1 F11 receptor F U R Iq21.2-q21.3 7.46 
AA877789 myosin VI M Y 0 6 6ql3 7.41 
X57348 strati fin SFN lp36.11 7.4 
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NM_022772.1 EPS8-related protein 2 EPS8L2 l l p l 5 . 5 7.29 
AFOOl294.1 pleckstrin homology-like domain, family A, member 2 PHLDA2 l l p l 5 . 5 7.29 
NM_001809.2 centromere protein A, 17kDa CENPA 2p24-p21 7.22 
NM_000695.2 aldehyde dehydrogenase 3 family, member B2 ALDH3B2 l l q l 3 7.09 
NM_022358.I potassium channel, subfamily K, member 15 KCNK15 20ql2-20ql3 6.97 
NM一014791.1 maternal embryonic leucine zipper kinase MELK 9pl3.2 6.95 
NM_007057.丨 ZWIO interactor ZWINT 10q21-q22 6.95 
L25541.1 laminin, beta 3 LAMBS lq32 6.93 
NM一018098.1 epithelial cell transforming sequence 2 oncogene ECT2 3q26.1-q26.2 6.8 
AF132818.1 Kruppel-like factor 5 (intestinal) KLF5 13q22.1 6.78 
BF343007 transcription factor AP-2 alpha (activating enhancer binding TFAP2A 6p24 6.78 
protein 2 alpha) 
NM_002774.1 kallikrein 6 (neurosin, zyme) KLK6 19ql3.3 6.64 
AW195581 G-protein signalling modulator 2 (AGS3-like, C. elegans) GPSM2 lpl3 .3 6.62 
NM_001109.1 a disintegrin and metalloproteinase domain 8 ADAM8 10q26.3 6.57 
NM_006456.1 ST6 ST6GALNA 17q25.1 6.55 
(alpha-N-acetyI-neuraminyl-2,3-beta-galactosyl-l,3)-N-acet C2 
ylgalactosaminide alpha-2,6-sialyItransferase 2 
M63310.1 annexin A3 ANXA3 4ql3-q22 6.53 
NM_003475.1 chromosome 11 open reading frame 13 C l l o r f l S l l p l 5 . 5 6.48 
AU151483 cadherin 6, type 2, K-cadherin (fetal kidney) CDH6 5pl5.1-pl4 6.46 
BC000076.1 cyclin D1 (PRADl: parathyroid adenomatosis 1) CCNDl l l q l 3 6.31 
NM_016448.1 RA-regulated nuclear matrix-associated protein RAMP 1 6.29 
NM_001408.1 cadherin, EGF LAG seven-pass G-type receptor 2 (flamingo CELSR2 lp21 6.26 
homolog, Drosophila) 
NM_001769.1 CD9 antigen (p24) CD9 12pl3.3 6.24 
BC003355.1 laminin, alpha 5 LAMAS 20ql3.2-ql3.3 6.07 
NM_025084.1 hypothetical protein FU22795 III hypothetical protein FU22795 15q25.2 6.05 
FLJ90297// /LOC388161 
U85658.1 transcription factor AP-2 gamma (activating enhancer TFAP2C 20ql3.2 5.98 
binding protein 2 gamma) 
NM一022449.丨 RAB17, member RAS oncogene family RAB17 2q37.3 5.96 
U52144.1 isocitratc dehydrogenase 2 (NADP+), mitochondrial IDH2 15q26.1 5.93 
NM_002224.1 inositol 1,4,5-triphosphate receptor, type 3 ITPR3 6p21 5.89 
NM_014333.1 immunoglobulin superfamily, member 4 IGSF4 1 lq23.2 5.88 
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NM_003258.1 thymidine kinase 1, soluble TKl 17q23.2-q25.3 5.86 
BF001806 antigen identified by monoclonal antibody Ki-67 MKI67 10q25-qter 5.82 
NM_002266.1 karyopherin alpha 2 (RAG cohort 1, importin alpha 1) KPNA2 17q23.1-q23.3 5.77 
BC002669.1 nuclear receptor subfamily 2, group F, member 6 NR2F6 19pl3.1 5.76 
NM_015888.丨 hook homolog 1 (Drosophila) HOOKl lp32.1 5.59 
NM_022121.1 PERP, TP53 apoptosis effector PERP 6q24 5.58 
NM_017780.1 chromodomain helicase DNA binding protein 7 CHD7 8ql2.2 5.44 
AW452623 solute carrier family 7 (cationic amino acid transporter, y+ SLC7A1 13ql2-ql4 5.44 
system), member 1 
NM .012105.1 beta-site APP-cleaving enzyme 2 BACE2 21q22.3 5.4 
U17714.1 suppression of tumorigenicity 13 (colon carcinoma) (Hsp70 ST13 22ql3.2 -4.97 
interacting protein) 
NM_001450.1 four and a half LIM domains 2 FHL2 2ql2-ql4 -5.12 
L22431.1 very low density lipoprotein receptor VLDLR 9p24 -5.14 
NM_003304.1 transient receptor potential cation channel, subfamily C, TRPCl 3q22-q24 -5.29 
member 1 
NM_031302.1 glycosyltransferase 8 domain containing 2 GLT8D2 12q -5.36 
A1J00170.1 Clone mRNA sequaice — — -5.43 
N91149 Chromosome 10 open reading frame 72 C10ort72 lOqll .23 -5.43 
NM_004684.1 SPARC-like 1 (mast9, hevin) SPARCLl 4q22.1 -5.46 
NM_018589.1 chromosome 14 open reading frame 116 CHESl 14q24.3-q32.11 -5.52 
NM_022117.1 cutaneous T-cell lymphoma-associated tumor antigen se20-4 TSPYL2 Xpl l .2 -5.59 
NM_004780.1 transcription elongation factor A (Sll)-like 1 TCEALl Xq22.1 -5.66 
NM_004503.1 homeoboxC6 H0XC6 12ql3.3 -5.67 
AI630848 TBCl domain family, member 4 TBC1D4 13q22.2 -5.68 
NM_015185.1 Cdc42 guanine nucleotide exchange factor (GEF) 9 ARHGEF9 Xql l .2 -5.69 
AB003476.1 A kinase (PRKA) anchor protein (gravin) 12 AKAP12 6q24-q25 -5.9 
NM_014799.1 hephaestin HEPH Xql l -q l2 -5.9 
AU145127 F-box and leiicine-rich repeat protein 7 FBXL7 5pl5.1 -5.96 
NM_000504.2 coagulation factor X FIO 13q34 -5.98 
NM_003243.1 transforming growth factor, beta receptor III (betaglycan, TGFBR3 Ip33-p32 -5.98 
300kDa) 
NM一005031.2 FXYD domain containing ion transport regulator 丨 FXYDI 19ql3.1 -6.04 
(phospholemman) 
NM_001564.1 inhibitor of growth family, member 2 ING2 4q35.1 -6.05 
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BF726212 ankyrin 2, neuronal ANK2 4q25-q27 -6.18 
NM__018013.1 Hypothetical protein FU10159 FU10159 6q21 -6.24 
NM_005308.1 G protein-coupled receptor kinase 5 GRK5 10q24-qter -6.25 
NM_018371.1 chondroitin beta 1,4 N-acetylgalactosaniinyltransferase ChGn 8p21.3 -6.28 
NM_002380.2 matrilin 2 MATN2 8q22 -6.28 
NM_000781.1 cytochrome P450, family 11，subfamily A, polypeptide 1 C Y P l l A l 15q23-q24 -6.3 
NM_006195.1 prc-B-cell leukemia transcription factor 3 PBX3 9q33-q34 -6.3 
R78668 cyclin-dependent kinase inhibitor IC (p57, Kip2) CDKNIC l l p l 5 . 5 -6.31 
NM_006226.1 phospholipase C-like 1 PLCLl 2q33 -6.38 
NM_023940.1 RAS-like, family 11, member B RASLl lB 4ql2 -6.39 
NM_004734.1 doublecortin and CaM kinasc-like 1 DCAMKLl 13ql3 -6.45 
NM_016608.1 ALEX 1 protein ARMCXl Xq21.33-q22.2 -6.47 
ALI 17515.1 phospholipase C-like 2 PLCL2 3p24.3 -6.59 
NM_003507.1 frizzled homolog 7 (Drosophila) FZD7 2q33 -6.63 
AF284095.1 adrenergic, alpha-2A-, receptor ADRA2A 10q24-q26 -6.65 
NM_001856.1 collagen, type XVI, alpha 1 C0L16A1 Ip35-p34 -6.66 
NM_000961.1 prostaglandin 12 (prostacyclin) synthase III prostaglandin 12 PTGIS 20ql3.1 l-ql3.13 -6.74 
(prostacyclin) synthase 
NM_006042.1 heparan sulfate (glucosamine)3-0-sulfotransferase 3A1 HS3ST3A1 17pl2-pl l .2 -6.75 
NM一006102.1 plasma glutamate carboxypeptidase PGCP 8q22.2 -6.75 
BF940043 nidogen (enactin) NID lq43 -6.8 
NM_002178.1 insulin-like growth factor binding protein 6 1GFBP6 12ql3 -6.81 
NM_015310.1 ADP-ribosylation factor guanine nucleotide factor 6 PSD3 8pter-p23.3 -6.82 
NM_025208.1 platelet derived growth factor D PDGFD l lq22.3 -6.88 
NM_003277.1 claudin 5 (transmembrane protein deleted in CLDN5 22qll .21 -6.9 
velocardiofacial syndrome) 
S77154.1 nuclear receptor subfamily 4, group A, member 2 NR4A2 2q22-q23 -6.9 
U50748.1 leptin receptor LEPR lp31 -7 
AW305097 olfactomedin-like 1 OLFMLl l l p l 5 . 4 -7 
NM_003070.1 SWl/SNF related, matrix associated, actin dependent SMARCA2 9p22.3 -7.02 
regulator of chromatin, subfamily a, member 2 
NM_004010.1 dystrophin (muscular dystrophy, Duchenne and Becker DMD DMD -7.07 
types) 
NM_000898.丨 monoamine oxidase B MAOB Xpl l .23 -7.08 
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NM_021730.1 NACHT, leucine rich repeat and PYD (pyrin domain) NALPl 17pl3 -7.09 
containing 1 
AI040163 calcium channel, voltage-dependent, beta 2 subunit CACNB2 10pl2 -7.1 
AA149644 junctional adhesion molecule 3 JAMS 1 lq25 -7.12 
D90453.1 caldesmon 1 CALDl 7q33 -7.18 
AI811298 odd-skipped related 2 (Drosophila) 0SR2 8q22.2 -7.21 
NM_004538.1 nucleosome assembly protein l-Iike 3 NAP1L3 Xq21.3-q22 -7.38 
BF062299 Protein tyrosine phosphatase’ receptor type, D PTPRD 9p23-p24.3 -7.39 
AI572079 snail homolog 2 (Drosophila) SNAI2 8ql l -7.41 
NM_014899.1 Rho-relaled BTB domain containing 3 RH0BTB3 5ql5 -7.43 
U35139.1 necdin homolog (mouse) NDN 15ql l .2-ql2 -7.46 
NM_016651.2 dapper homolog 1, antagonist of beta-catenin (xenopus) DACTl 14q23.1 -7.49 
NM_014668.1 GREBl protein GREBl 2p25.1 -7.54 
NM_004430.1 early growth response 3 EGR3 8p23-p21 -7.64 
NM_000901.1 nuclear receptor subfamily 3, group C, member 2 NR3C2 4q31.1 -7.64 
NM_016593.1 cytochrome P450, family 39, subfamily A, polypeptide 1 CYP39AI 6p21.1-pll .2 -7.68 
AF063606.1 transcription elongation factor A (Sll)-like 2 TCEAL2 Xq22.1-q22.3 -7.74 
R72286 microtlbrillar-associated protein 4 MFAP4 17pll .2 -7.78 
NM_001159.2 aldehyde oxidase 1 AOXl 2q33 -7.79 
NM_007116.1 tcnascin XB TNXB 6p21.3 -7.8 
AI623989 angiotensin I converting enzyme (pepticiyl-dipeptidase A) 1 ACE 17q23 -7.85 
AF055376.1 v-maf musculoaponeurotic fibrosarcoma oncogene homolog MAF 16q22-q23 -7.92 
(avian) 
X04697.1 complement factor H CFH lq32 -7.95 
NM_014795.1 zinc finger homeobox lb ZFHXIB 2q22 -7.98 
BF514079 Kruppel-like factor 4 (gut) KLF4 9q31 -7.99 
NM_003573.1 latent transforming growth factor beta binding protein 4 LTBP4 19ql3.1-ql3.2 -8.07 
A1818409 KIAA0774 KIAA0774 13ql2.3 -8.1 
NM_016250.1 NDRG family member2 NDRG2 14qll .2 -8.17 
AL554245 nuclear rcceptor subfamily 2, group F, member 2 NR2F2 15q26 -8.26 
NM_000689.1 aldehyde dehydrogenase 1 family’ member A1 ALDHlAl 9q21.13 -8.3 
NM_021076.1 neurofilament, heavy polypeptide 200kDa NEFH 22ql2.2 -8.35 
NM_030761.1 wingless-type MMTV integration site family, member 4 III WNT4 Ip36.23-p35.1 -8.43 
wingless-type MMTV integration site family, member 4 
NM-002736.1 protein kinase, amp-dependent, regulatory, type II, beta PRKAR2B 7q22 -8.44 
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NM一001797.1 cadherin 11, type 2, OB-cadherin (osteoblast) CDHll 16q22.1 -8.51 
AF065389.1 transmembrane 4 superfamily member 9 III transmembrane TM4SF9 4q23 -8.54 
4 superfamily member 9 
NM_002135.1 nuclear receptor subfamily 4, group A, member 1 NR4A1 12ql3 -8.57 
AI825798 Rap2-binding protein 9 RPIB9 7q21.12 -8.69 
ABOl 1106.1 attractin-like 1 ATRNLl 10q26 -8.76 
NM_002222.I inositol 1,4,5-triphosphate receptor, type 1 ITPRl 3p26-p25 -8.76 
AI367275 acyl-Coenzyme A dehydrogenase, long chain ACADL 2q34-q35 -8.78 
U15979.丨 delta-like 丨 homolog (Drosophila) DLKl DLICl -8.81 
U79271.1 V-akt murine thymoma viral oncogene homolog 3 (protein AKT3 Iq43-q44 -9.08 
kinase B, gamma) 
L27560.I insulin-like growth factor binding protein 5 IGFBP5 2q33-q36 -9.13 
NM_000587.1 complement component 7 C7 5pl3 -9.36 
NM_003212.1 teratocarcinoma-derived growth factor 1 TDGFl 3p21.31 -9.41 
NM_016206.1 colon carcinoma related protein VGL-3 3pl2.1 -9.5 
NM_001771.丨 CD22 antigen CD22 19ql3.1 -9.51 
N22468 MADS box transcription enhancer factor 2, polypeptide C MEF2C 5ql4 -9.54 
(myocyte enhancer factor 2C) 
BF449063 collagcn, type XIV, alpha 1 (undulin) C0L14A1 -9.62 
NM_006206.1 platelet-derived growth factor receptor, alpha polypeptide PDGFRA 4ql l -ql3 -9.82 
NM_021219.1 jimctional adhesion molecule 2 JAM2 21q21.2 -9.87 
NM_000702.1 ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide ATP1A2 Iq21-q23 -9.88 
NM_012082.2 zinc finger protein, multitype 2 ZFPM2 8q23 -9.89 
AF138300.1 decorin DCN 12ql3.2 -10.11 
U 19495.1 chemokine (C-X-C motif) ligand 12 (stromal cell-derived CXCL12 lOqll. l -10.27 
factor 1) 
NM_012342.1 BMP and activin membrane-bound inhibitor homolog BAMBI 10pl2.3-pl 1.2 -10.31 
(Xenopus laevis) 
NM_020190.1 HNOEL-iso protein 0LFML3 lpl3.2 -10.46 
NM_000025.1 adrenergic, beta-3-, receptor ADRB3 8pl2-pl l .2 -10.56 
NM_014057.1 osleoglycin (osteoinductive factor, mimecan) OGN 9q22 -10.68 
NM_002101.2 glycophorin C (Gerbich blood group) GYPC 2ql4-q21 -10.77 
NM_013231.1 fibronectin leucine rich transmembrane protein 2 FLRT2 14q24-q32 -11.15 
NM_007046.1 elastin microfibril interface located protein EMILINI 2p23.3-p23.2 -11.47 
U05682.1 TYR03 protein tyrosine kinase TYR03 15ql5.1-q21.1 -11.48 
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NM_001145.1 angiogenin, ribonuclease, Rnase A family, 5 ANG 14ql 1.1-ql 1.2 -11.59 
NM—001174.2 Rho GTPase activating protein 6 ARHGAP6 Xp22.3 -11.6 
NM_004826.1 endothelin converting enzyme-like 1 ECELl 2q36-q37 -11.6 
NM_0245]2.1 leucine rich repeat containing 2 LRRC2 3p21.31 -11.67 
NM_000242.1 mannose-binding lectin (protein C) 2’ soluble (opsonic defect) MBL2 lOql 1.2-q21 -11.68 
AL569804 PDZ domain containing RING finger 3 PDZRN3 3pl3 -11.94 
AA707199 neurotrophic tyrosine kinase, receptor, type 2 NTRK2 9q22.1 -12.29 
BE906572 UDP-N-acetyl-alpha-D-galactosamine:polypeptide GALNTIO 5q33.2 -12.34 
N-acetylgalactosaminyltransferase 10 (GalNAc-TlO) 
NM一005114.1 heparan sulfate (glucosamine) 3-0-sulfotransferase 1 HS3ST1 4pl6 -12.39 
NM_(X)2847.1 protein tyrosine phosphatase, receptor type, N polypeptide 2 PTPRN2 7q36 -12.39 
NM_007038.1 a disintegrin-like and metalloprotease (reprolysin type) with ADAMTS5 21q21.3 -12.45 
thrombospondin type 1 motif, 5 (aggrecanase-2) 
NM_014880.1 C-type lectin BIMLEC precursor CD302 2q24.2 -12.7 
NM_018203.1 hypothetical protein FU10748 FLJ10748 lq32.1 -12.84 
AL021786 integral membrane protein 2A ITM2A Xql3.3-Xq21.2 -13.12 
NM_006211.1 proenkephalin PENK 8q23-q24 -13.39 
NM_000851.1 glutathione S-transferase M5 GSTM5 lpl3.3 -13.75 
NM_024574.1 hypothetical protein FU23191 FLJ23191 4q27 -13.93 
AI761728 ribonuclease, Rnase A family, 4 RNASE4 Mql l . l -14.13 
NM_0180I5.2 hypothetical protein FU10178 FU10178 Xq22.3 -14.46 
AI810712 hepatic leukemia factor HLF 17q22 -14.64 
AF349719.1 trophinin III irophinin TRO Xpll.22-p 11.21 -15.12 
NM_005824.1 leucine rich repeat containing 17 LRRC17 7q22.1 -15.2 
NM_001393.1 extracellular matrix protein 2, female organ and adipocyte ECM2 9q22.3 -15.67 
specific 
NM_0(X)222.1 v-kil Hardy-Zuckerman 4 feline sarcoma viral oncogene KIT 4q l l -q l2 -15.81 
homolog 
AK021882.1 DIRAS family, GTP-binding RAS-like 3 DIRAS3 lp31 -16.8 
NM_003240.1 left-right determination factor 2 LEFTY2 lq42.1 -17.03 
NM_017938.1 hypothetical protein FU20716 FU20716 Xq24 -17.21 
AA099357 ATP-binding cassette, sub-family A (ABCl) , member 6 ABCA6 17q24.3 -17.42 
NM_016569.1 T-box 3 (ulnar mammary syndrome) TBX3 12q24.1 -18.81 
NM_012134.1 leiomodin 1 (smooth muscle) LMODl lq32 -18.83 
NM_023067.1 forkhead box L2 F0XL2 3q23 -18.93 
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NM_014710.1 G protein-coupled receptor associated sorting protein 1 GPRASPl Xq22.1 -20.85 
NM_001482.1 glycine amidinotransferase (L-arginine:glycine GATM 15q21.1 -21.85 
amidinolransferase) 
NM_005460.1 synuclein, alpha interacting protein (synphilin) SNCAIP 5q23.1-q23.i -22.09 
AUl 18882 endothelin receptor type A EDNRA 4q31.22-q31.23 -22.6 
AL023553 RNA-binding protein pippin PIPPIN 22ql3.2-q 13.31 -23.83 
NM_017933.1 hypothetical protein FU20701 III hypothetical protein FLJ20701 2q36.3 -24.05 
FU20701 
NM_(XX)349.1 steroidogenic acute regulator STAR 8pll.2 -26.67 
NM_007168.1 ATP-binding cassette, sub-family A (ABCl) , member 8 ABCA8 17q24 -28.23 
NM_016270.1 Kruppel-like factor 2 (lung) KLF2 19pl3.13-pl3.11 -30.65 
NM_022844.1 myosin, heavy polypeptide 11, smooth muscle MYHll 16pl3.13-pl3.12 -30.67 
BF939489 glycoprotein M6A GPM6A 4q34 -31.03 
AI078169 laminin, alpha 2 (merosin, congenital muscular dystrophy) LAMA2 6q22-q23 -39.12 
NM_003206.1 transcription factor 21 TCF21 6pter-qter -43.48 
NM_003881.1 WNTl inducible signaling pathway protein 2 WISP2 20ql2-ql3.1 -51.26 
AF208967.1 paternally expressed 3 PEG3 19ql3.4 -59.69 
AI768628 chloride intracellular channel 2 CLIC2 Xq28 -173.59 
AL158172 phospholipase A2, group V PLA2G5 Ip36-p34 -185.72 
NM_017718.1 dedicator of cytokinesis 10 DOCK 10 2q36.3 -200.7 
NM_019886.1 carbohydrate (N-acctylglucosamine 6 -0 ) sulfotransferase 7 CHST7 Xp 11.23 -270.83 
NM_003014.2 secreted frizzled-related protein 4 SFRP4 7pl4.1 -333.29 
AV708130 scavenger receptor class B, member 1 SCARBl 12q24.31 -342.92 
AA530892 dual specificity phosphatase 1 DUSPl 5q34 -383.55 
AV700724 GATA binding protein 4 GATA4 8p23.1-p22 -403.21 
NM_005794.1 dehydrogenase/reductase (SDR family) member 2 DHRS2 14qll.2 -426.91 
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Table 3.2 Genes previously identified as differentially regulated in epithelial serous 
ovarian cancer tissue in our gene list. 
Accession no. Geme name Gene symbol Fold change References 
L33930 CD24 antigen (small cell CD24 1807.87 Santin et al., 2004 
lung carcinoma cluster 4 
antigen) 
NM_024690.1 mucin 16 MUC16 1156.6 McLemore and Aouizerat et al., 
2005; Lewis and Menon et al , 
2003 
BC002700.1 keratin 7 KRT7 801.55 Cathro and Stoler et al., 2002 
NM_005978.2 SI00 calcium binding protein S100A2 223.3 Santin et al., 2004 
A2 
AI610869 Mucin 1, transmembrane MUCl 167.2 Feng et al., 2002; Drapkin et al , 
2004 
NM_005564.1 lipocalin 2 (oncogene 24p3) LCN2 86.49 Santin et al., 2004 
BG170541 met proto-oncogene MET 46.78 Huntsman et al., 1999 
(hepatocyte growth factor 
receptor) 
NM_001067.1 topoisomerase (DNA) II alpha T0P2A 45.86 Brustmann H et al., 2004 
IVOkDa 
NM_005823.2 mesothelin MSLN 34.67 Schaner et al., 2003; Drapkin et 
al., 2004 
NM_005562.1 laminin, gamma 2 LAMC2 22.2 Santin et al , 2004 
NM_006103.1 WAP four-disulfide core WFDC2 20.49 Drapkin et al., 2004 
domain 2 
NM_006853.1 kallikrein 11 KLKll 18.38 Borgono et al., 2003 
NM_007196.1 kallikrein 8 (neuropsin/ovasin) KLK8 16.89 Shigeniasa et al., 2004 
NM_004415.1 desmoplakin (DPI, DPII) DSP 13.63 Cao et al., 2004 
NM_005558.1 ladinin 1 LADl 13.49 Santin et al , 2004 
NM_020387.1 RAB25, member RAS RAB25 8.34 Cheng et al., 2004 
oncogene family 
NM_002193.1 inhibin, beta B (activin AB INHBB 8 Reis et al., 2000 
beta polypeptide) 
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NM_005046.1 kallikrein 7 (chymotryptic, KLK7 7.82 Dong et al., 2003 
stratum comeum) 
X57348 slratifin SFN 7.4 Santin et al., 2004 
NM一002774.1 kallikrein 6 (neurosin, zyme) KLK6 6.64 Hoffman et a l , 2002 
BC000076.1 cyclin D1 ( P R A D l : C C N D l 6.31 Bali et al., 2004 
parathyroid adenomatosis 1) 
B F 0 0 I 8 0 6 antigen identified by MKI67 5.82 Suo et al., 2004 
monoclonal antibody Ki-67 
NM_018589 .1 chromosome 14 open CHESl -5.52 Sawiris et al., 2002 
reading frame 116 
N M _ 0 0 3 2 7 7 . 1 claudin 5 (transmembrane CLDN5 -6.9 Santin et al., 2004 
protein deleted in 
velocardiofacial syndrome) 
NM_006206.1 platelet-derived growth factor PDGFRA -9.82 Lassus et al., 2004; Dabrow et 
receptor, alpha polypeptide al., 1998 
NM_000222.1 v-kit Hardy-Zuckerman 4 KIT -15.81 Lassus et al., 2004; Schmandt et 
feline sarcoma viral oncogene al., 2003 
homolog 
A A 5 3 0 8 9 2 dual specificity phosphatase D U S P l -383.55 Givant-Horwitz et la., 2004 
1 
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Figure 3.2 Hierarchical clustering (p-value < 0,001) picture of the differentially 
regulated (fold change > 4) genes in Serous Epithelial Ovarian Tumor compared to 
Normal Ovary. Red represents the up-regulated probe sets while blue represents the 
down-regulated probe sets. 
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Figure 3.3 Annotation classification (p-value < 0.001) of the differentially expressed 
genes in Serous Epithelial Ovarian Tumor compared to Normal Ovary. Distributions 
of the GO terms under a) Molecular function, b) Cellular component and c) 
Biological process are shown. 
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3.1.2.2 Gene expression profiles distinguish Advanced Stage Serous Epithelial 
Ovarian Tumor from Early Stage Serous Epithelial Ovarian Tumor and 
identify differentially expressed genes 
Using (1) lower bound fold change larger than 2; (2) p-value for t-test less than 
0.01 to compare advanced stage and early stage tumor samples, 10 probe sets 
representing 10 genes were obtained with 10% median false discovery rate (FDR) 
by 100 permutations. Among the 10 genes, 9 were up-regulated and 1 was 
down-regulated in advanced stage ovarian cancers. The gene list is shown in Table 
3.3. The hierarchical clustering (p-value < 0.001) picture of the differentially 
expressed genes is shown in Figure 3.4. The early and advanced stage tumor 
samples separate well, the early stage arrays behave very consistently across 
different samples. 
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Table 3.3 List of differentially regulated (fold change > 2; p-value < 0.01) genes in 
Advanced Stage Serous Epithelial Ovarian Tumor compared to Early Stage Serous 
Epithelial Ovarian Tumor.  
Accession no. Gene name Gene symbol Fold change 
NM_014178.1 syntaxin binding protein 6 (amisyn) STXBP6 15.53 
BE858180 paternally expressed 10 PEGIO 4.98 
NM_015507.2 EGF-like-domain, multiple 6 EGFL6 4.62 
NM_(X)4362.1 calmegin CLGN 4.48 
AF186255.1 sulfotransferase family, cytosolic, IC, member 1 SULTICI 4.23 
NM_017522.1 low density lipoprotein receptor-related protein 8, LRP8 3.77 
apolipoprotein e receptor 
NM_(X)4181.1 ubiquitin carboxyl-terminal esterase LI (ubiquitin UCHLl 3.67 
thiolesterase) 
M33653.1 collagen, type XIII, alpha 1 COL13A 3.49 
AI754404 procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine PLOD2 3.16 
hydroxylase) 2 
AB041269.1 keratin 19 pseudogene LOC160313 -102.68 
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Figure 3.4 Hierarchical clustering (p-value < 0.001) picture of the differentially 
regulated (fold change > 2) genes in Advanced Stage Serous Epithelial Ovarian 
Tumor compared to Early Stage Serous Epithelial Ovarian Tumor. Red represents the 
up-regulated probe sets while blue represents the down-regulated probe sets. 
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3.1.2.3 Gene expression profiles distinguish Metastatic Serous Epithelial Ovarian 
Tumor from Primary Serous Epithelial Ovarian Tumor and identify 
differentially expressed genes 
Using 1) lower bound fold change > 1.5; 2) p-value for paired t-test < 0.05 to 
compare paired metastatic and primary ovarian cancer samples, 21 probe sets 
representing 20 genes were obtained with 22.2% median false discovery rate (FDR) 
by 100 permutations. Among the 20 genes, 18 were up-regulated and 2 were 
down-regulated in metastatic cancers. The gene list is shown in Table 3.4. Since the 
sample size is very small (4 primary tumors vs. 4 metastatic tumors), fold change 
criteria was relaxed to 1.5 to detect more subtle changes and get a larger gene list. 
Figure 3.5 shows the hierarchical clustering (p-value < 0.001) picture of the 
differentially expressed genes. The primary and metastatic cancer samples separate 
well. 
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Table 3.4 List of differentially regulated (fold change > 1.5; paired p-value < 0.05) 
genes in Metastatic Serous Epithelial Ovarian Tumor compared to Primary Serous 
Epithelial Ovarian Tumor. 
Accession no Gene name Gene symbol fold change 
NM_002160.1 tenascin C (hexabrachion) TNC 12.58 
NM_000602.1 serine (or cysteine) proteinase inhibitor, clade E (nexin, SERPINEl 8.53 
plasminogen activator inhibitor type 1), member 1 
NM_002658.1 plasminogen activator, urokinase PLAU 3.69 
NM_001423.1 epithelial membrane protein 1 EMPl 3.19 
NM_019034.1 ras homolog gene family, member F (in filopodia) RHOF 3.14 
ABOl 1138.1 ATPase, Class V, type lOA ATP 1 OA 2.67 
AL136139 enhancer of filamentation 1 NEDD9 2.64 
NM_014745.1 K1AA0233 gene product FAM38A 2.54 
AF087853.1 growth arrest and DNA-damage-inducible, beta GADD45B 2.48 
BE965029 Homo sapiens cDNA: F U 2 1 5 3 3 fis, clone COL06072. - 2.45 
NM_003407.1 zinc finger protein 36，C3H type, homolog (mouse) ZFP36 2.39 
NM_001114.1 adenylate cyclase 7 ADCY7 2.35 
NM_003887.1 development and differentiation enhancing factor 2 DDEF2 2.29 
AV733950 early growth response 1 EGRl 2.21 
AF047245.1 immunoglobulin lambda joining 3 !GLJ3 2.19 
NM_006670.1 trophoblast glycoprotein TPBG 2.19 
NM_005572.1 lamin A/C LMNA 2.15 
NM_017784.1 oxyslerol binding protein-like 10 OSBLIO 2.1 
AK024896.1 Homo sapiens cDNA: F U 2 1 2 4 3 fis, clone COLOl 164. - -2.61 
BGl 10231 poly(A) polymerase alpha -3.43 
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Figure 3.5 Hierarchical clustering (p-value < 0.001) picture of the differentially 
regulated (fold change > 1.5) genes in Metastatic Cancers of ovary origin compared 
to Primary Serous Epithelial Ovarian Cancers. Red represents the up-regulated probe 
sets while blue represents the down-regulated probe sets. 
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3.2 Validation of microarray data by quantitative Real-time PCR 
Quantitative Real-time PCR was performed to validate the microarray results. 
In the three comparisons of micrarray, genes with high fold change and under the 
functional annotations of interest were picked up as candidate genes for validation. 
Sample size for the validation was enlarged to 137，in which non-serous type 
epithelial ovarian tumor samples were also included. In the 137 cases, 19 were 
normal ovaries, 108 were epithelial ovarian cancers (39 serous type, 28 endometioid 
type, 17 mucinous type, 17 clear-cell type and 7 andocarcinomas) and 10 were 
metastatic cancers of ovary origin. 
3.2.1 Fold change of candidate genes 
Table 3.5 shows the list of results from Real-time PCR validation of the 
candidate genes selected from the three comparisons. Differences among the test and 
control groups were determined by Mann-Whitney U Test at 95% confidence 
interval. All the 15 genes from comparison of tumor versus normal ovary showed 
significant fold change in real-time PCR, but only C0L13A1 showed significant 
difference from comparisons of early versus advanced stage tumor and only TNC 
showed significant fold change from comparisons primary versus metastatic cancer. 
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Table 3.5 List of Fold change (FC) of the candidate genes from the Real-time PCR 
validation results. 
Gene FC for Microarray FC for Real-time PCR 
symbol Serous Endometrioid Clear-Cell Mucinous 
a) Gene selected from comparison of Ovarian Tumor vs Normal Ovary 
CCNAl 37.64 (p=.000) 77.14 (p=.000) 165.89 (p=.004) 27.15 (p=.037) 28.53 (p-019) 
BIRC5 134.38 (p=.000) 107.87 (p=.000) 139.02 (p=.000) 57.44 (p=.000) 92.49 (p=.000) 
CCNB2 8.93 (p=.000) 87.64 (p=.000) 174.18 (p=.000) 71.04 (p=.000) 99.23 (p=.000) 
CDC2 7.69 (p=.000) 77.08 (p=.000) 169.66 (p=.000) 58.06 (p=.000) 85.79 (p-.OOO) 
KNTC2 11.58 (p=.000) 72.91 (p=.000) 69.63 (p=.000) 41.29 (p=.000) 59.54 (p=.000) 
TIK 11.02 (p=.000) 67.82 (p=.000) 106.92 (p=.000) 54.62 (p=.000) 54.13 (p=.000) 
T0P2A 45.86 (p=.000) 59.97 (p=.000) 82.97 (p=.000) 53.17 (p=.000) 75.47 (p=.000) 
NEK2 33.45 (p=.000) 52.85 (p=.000) 80.00 (p=.000) 44.88 (p=.000) 75.56 (p=.000) 
BUB IB 9.08 (p=.000) 49.71 (p=.000) 121.25 (p=.000) 27.43 (p=.000) 45.16 (p-.OOO) 
HCAPG 12.67 (p=.000) 35.45 (p=.000) 49.90 (p=.000) 18.17 (p=.000) 26.58 (p=.000) 
CCNEl 19.78 (p=.000) 29.77 (p=.000) 54.81 (p=.000) 60.18 (p=.000) 24.15 (p=.000) 
REC8L1 12.18 (p=.000) 23.35 (p=.000) 110.10 (p=.002) 5.44 (p=.508) 17.25 (p=.000) 
KPNA2 5.77 (p=.000) 11.33 (p=.000) 11.50 (p=.000) 12.19 (p=.000) 7.86 (p=.000) 
CDKNIC -16.80 (p=.000) -1.70 (p=.000) -2.41 (p=.000) -4.51 (p=.000) -1.25 (p=.004) 
DIRAS2 -6.16 (p=.000) -3.28 (p=.000) -4.15 (p 二 . 0 0 0 ) -7.26 (p=.000) -2.07 (p=.001) 
b) Genes selected front the comparison of Advanced Stage Ovarian Tumor vs Early Stage Ovarian Tumor 
EGFL6 4.62 (p=.003) 13.49 (p=.304) 1.93 (p=.290) -1.38 (p=.758) 51.09 (p=.787) 
PEG 10 4.98 (p=.000) 2.34 (p=.323) -2.27 (p=.923) -3.01 (p=.758) 1.35 (p=.197) 
C0L13A 3.49 (p=.003) 1.27 (p=.003) -3.33 (p=.564) -13.56 (p=.280) 3.39 (p=.606) 
STXBP6 15.53 (p=.002) 1.23 (p=.470) -1.07 (p=.773) 1.23 (p=.217) 3.53 (p=.071) 
PLOD2 3.16 (p=.000) 1.16 (p 二 . 6 2 1 ) 1.57 (p=.847) -2.05 (p=.280) 2.80 (p=.071) 
c) Genes selected from comparison of Metastatic Cancer vs Primary Ovarian Cancer 
TNC 12.58 (p=.005) 9.73 (p=.012) 
SERF IN El 8.53 (p=.040) 6.49 (p=.123) 
PLAU 3.69 (p=.038) 2.25 (p=.674) 
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3.2.2 Correlation between microarray and quantitative real-time PCR results 
Table 3.6 shows the Pearson product-moment correlation of microarray and 
real-time PCR expression results at 95 % confidence interval. More than half (65 %) 
of the candidate genes showed significant correlation between microarray and 
real-time PCR results, all the candidate genes showed the same trend of direction of 
fold change from the two experiments. Figure 3.6 shows the trend of fold change 
obtained from microarray and Real-time PCR of each candidate gene. 
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Table 3.6 Pearson product-moment correlation of the expression of candidate genes 
of microarray and Real-time PCR. 
Pearson correlation p-value 
a) Gene selected from comparison of Ovarian Tumor vs Normal Ovary 
CCNAl 0.718 0.000 
BIRC5 0.455 0.017 
CCNB2 0.327 0.096 
CDC2 0.491 0.009 
KNTC2 0.326 0.097 
TTK 0.180 0.370 
TOP2A 0.527 0.005 
NEK2 0.534 0.004 
BUBIB 0.188 0.347 
HCAPG 0.223 0.264 
CCNEl 0.637 0.000 
RFX8L1 0.5 丨 9 0.006 
KPNA2 0.585 0.001 
CDKNI C 0.466 0.014 
DIRAS2 0.336 0.086 
b) Genes selected from the comparison of Advanced Stage Ovarian Tumor vs Early Stage Ovarian Tumor 
EGFL6 0.781 0.000 
PEGIO 0.442 0.031 
COL13A 0.726 0.000 
STXBI'6 0.456 0.025 
PLOD2 0.535 0.007 
c) Genes selected from comparison of Metastatic Ovarian Cancer vs Primary Ovarian Cancer 
TNC 0.394 0.335 
SERPINEl 0.733 0.039 
PLAII 0.651 0.081 
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3.2.3 Comparison of the expression of candidates genes among the different 
histological types of epithelial ovarian tumors 
Differences of expression of candidate genes among different histological types 
of epithelial ovarian tumors were determined by Kmskal-Wallis Test and 
Mann-Whitney U Test at 95 % confidence interval. 
Only the candidate genes showing significant fold change at 95% confidence 
level (with reference to Table 3.4) in ovarian tumor of non-serous epithelial type 
were subjected to the test. The significant difference of expression of candidate 
genes between different histological types of ovarian tumor is shown in Table 3.6. It 
showed that there was at least on difference among the histological groups of tumor 
for the genes CCNAl (p=0.000), REC8L1 (p=0.006) and CCNEl (p=0.000). 
The results stated above shows that there is at least one difference among the 
four histological groups of ovarian tumor for the genes. Therefore, Mami-Whitney 
Rank Test was performed to investigate the allocation of differences. For CCNAl, 
there is significant difference in fold change between serous and mucinous type 
ovarian tumors (p=0.012). For REC8L1 and CCNEl, there are significant 
differences in fold change between serous and clear-cell type ovarian tumors 
(p=0.003 and p=0.001 respectively). The result is shown in Table 3.7. 
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Table 3.6 Kruskal Wallis Test for the significant difference in expression of 
candidate genes between different histological types of ovarian tumor. 
Test Statistics (Kruskal Wallis Test)  
ICCNAL ICDKNIC [CDC2 [DIRAS2 |KPNA2 
C h i - S q u a r e 8 . 0 6 8 i m 
df 3 3 3 3 3 
p-value |0.045 |o.869 |o.336 |o.l78 |o.36 
IRECSLI |T0P2A [CCNB2 |KNTC2 I N E ^ 
C h i - S q u a r e ^ ^ LTO ^ 
df 3 3 3 3 3 
p-value | 0 .026 |o.399 |Q.617 0 . 8 1 2 |Q.279 
IHCAPG ITTK IccNEi IBUBIB |BIRC5 
C h i - S q u a r e ^ V m 1 1 . 7 9 8 i m L ^ 
df 3 3 3 3 3 
p-value [Q.632 [O.826 |O.QQ8 |O.407 |O.745 
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Table 3.7 Mann-Whitney Rank Test for the difference of fold change from 
Real-time PCR among the four histological groups of ovarian tumor, a) CCNAl; b) 
CCNEl and c)REC8Ll. 
Ranks 
a)  
Group N Mean Rank Sum of Ranks 
CCNAl Serous 37 27.27 
Mucinous 11 15.18 ^  
Total 48 
Test Statistics  
CCNAl 
Mann-Whitney U 101 
Wilcoxon W 167 
Z -2.514 
p-value 0.012 
, � Ranks 
b)  
Group N Mean Rank Sum of Ranks 
CCNEl Serous 37 22.54 ^  
Clear-cell 16 37.31 
Total 53 
Test Statistics  
CCNEl 
Mann-Whitney U 131 
Wilcoxon W 834 
Z -3.197 
p-value 0.001 
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Group N Mean Rank Sum of Ranks 
REC8L1 Serous 37 31.08 1150 




Mann-Whitney U 145 
Wilcoxon W 'm  
Z -2.926 
p-value 0.003 
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CHAPTER 4 DISCUSSION 
4.1 Global gene expression profiling using oligonucleotide microarray 
4.1.1 Sensitivity, specificity and reproducibility of the Affymetrix GeneChip® 
microarray 
Gene expression profiling is a powerful tool for identifying aberrant gene 
expression patterns associated with the processes of tumorogenesis. A number of 
studies have been published reporting the use of Affymetrix GeneChip® microarray 
to identify genes that are differentially regulated in cancers compared to the normal 
organs (Maitra et al., 2003; Grutzmann et al., 2004) and in metastatic cancers 
compared to their origins (De Lange et al., 2001; Trojan et al., 2005). Almost all 
these studies provided valuable information. 
In Affymetrix ’s oligonucleotide microarray, the 25-oligomer probes are designed 
to uniquely represent the desired cognate gene through blasting the GenBank 
database, thus minimizing cross-hybridization between similar sequences (Lipshutz et 
al., 1995; Lockhart et a l , 1996). Using oligonucleotides also makes it easier to design 
and select probes from the same or different genes with similar guanine and cytosine 
content and putative melting temperature. Other criteria for the selection of probes 
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include unique sequence, minimum secondary structures, and 3' terminal sequence 
selection, all of which serve to insure greater specificity in the probe-target binding. 
The oligonucleotide approach for the analysis of gene expression has been 
criticized for a lack of sensitivity (Schulze and Downward, 2001). Since a single 
capture probe is not always sufficient to distinguish the expression of a particular 
gene, the use of multiple capture probes to represent a single gene in the Affymetrix 
array system is intended to avoid the problem of cross-hybridization as well as to 
increase sensitivity. Thus, one of the likely causes of increased specificity in 
oligonucleotide arrays, as compared with long cDNA arrays, is a decrease in 
cross-hybridization with highly homologous genes. 
A basic property of a good microarray platform is high reproducibility in 
repeated experiments. One way to measure reproducibility within a platform is to 
measure a correlation coefficient between the fold changes of all genes in replicate 
chips. An evaluation study has demonstrated that the correlation for within-platform 
reproducibility is high for Affymetrix microarray platform (Park et al , 2004). In our 
experiments, moreover, some of the genes were detected with more than one probe 
set showing the same trend of expression, indicating a considerable reproducibility of 
the method. 
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4.1.2 Microarray analysis software 
4.1.2.1 DNA-Chip Analyzer software 
DNA-Chip Analyzer (dChip) (www.dchip.org) is a software package 
implementing model-based expression analysis of oligonucleotide arrays and several 
high-level analysis procedures. It is free software available to academic users. A 
statistical model for one probe set in multiple arrays to account for the probe 
variability in computing expression levels was proposed by Li and Wong (2001a): 
Pij = PMij - MMij = ei(j)j + 8ij, E(t)'j = J, 8ij �N (0，cj2) 
It states that the difference between perfect-match and mis-match (PM - MM) 
in array I，probe j of this probe set is the product of the model-based expression index 
(MBEI) in array i (0i) and the probe-sensitivity index of probe j (([)」)，plus random 
error. J is the number of probe pairs in the probe set, the number of probe pairs is 11 
in the array we used. Fitting the model, cross-hybridizing probes (屯、with large 
standard error, which are excluded during iterative fitting) and arrays with image 
contamination at the probe set (0i's with large standard error) as well as single 
outliers (image spikes) can be identified. Therefore, errors due to cross-hybridizing 
probes and image contamination can be reduced. 
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High-level analysis in dChip includes comparative analysis and hierarchical 
clustering. Given two samples or two groups of samples, genes that are reliably 
differentially expressed between the two groups can be identified. The clustering 
algorithm of genes relies on the distance between two genes. Before clustering, the 
expression values for a gene across all samples are standardized (linearly scaled) to 
have mean 0 and standard deviation 1，and these standardized values are used to 
calculate correlations between genes and samples and serve as the basis for merging 
nodes. The distance between two genes is defined as 1 - r where r is the correlation 
coefficient between the standardized values of the two genes across samples. Two 
genes with the closest distance are first merged into a supergene and connected by 
branched with length representing their distance and are then deleted for future 
merging. The expression level of the newly formed supergene is the average of 
standardized expression levels of the two genes across samples. Then, the next pair 
of genes (or supergenes) with the smallest distance is chosen to merge, and the 
process is repeated n - 1 times to merge all the n genes. A similar procedure is used 
to cluster samples. 
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4.1.2.2 Comparison of statistical methods for analysis of Affymetrix GeneChip® 
microarray data 
A number of methods have been developed to quantify gene expression 
abundance from GeneChip® expression data using different probe measures and 
summary schemes. Among them, Microarray Suite 5.0 (MAS 5.0; Liu et al., 2002; 
Hubbel et a l , 2002), Rosetta Resolver® v3.1 (Stouhgton and Dai, 2002; Roberts et 
al., 2002), dChip (Li and Wong, 2001a, b) are the best known. In MAS 5.0， 
Affymetrix computes an "ideal mismatch" (IM) based on missing data theory such 
that PM-IM is always greater than zero. Then, all probe pairs are used to estimate a 
gene expression value based on Tukey's Biweight algorithm. However, even with the 
use of IM, the variation among probes could be greater than between samples. It 
estimates a common mean non-specific hybridization background (for an entire chip) 
from PM using a convolution model and then subtracts this background from PM. 
Resolver® computes the signal for each probe set by averaging the PM - MM 
intensities for the probe pairs after discarding values that lie outside 3 standard 
deviations from the mean. No attempt is made to adjust MM values that are larger 
than their corresponding PM values, so a negative signal may be estimated for many 
probe sets. 
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Resolver, MAS5，and the version of dChip perform well in quantifying gene 
expression (Rajagoplan, 2003). However, the PM-only version of the dChip model 
performs poorly. The PM only model is used only when the mismatch signals is 
higher than the perfect match signals and negative MBEI expression values is 
resulted in majority of probe sets. This algorithm uses only PM probes to calculate 
all-positive expression value. Therefore, it dose not appear advisable to use the PM 
only model for microarray analysis. In the present study, PM - MM model was used 
instead of PM-only model. 
The performance of Resolver and MASS in detecting 2-fold change in transcript 
concentration is far superior to that of dChip (Rajagoplan, 2003). At a comparable 
false positive rate, Resolver and MAS5 are able to detect more true changes in 
transcript concentration. These three methods perform best at detecting concentration 
changes at intermediate concentrations, and their accuracy falls off at low and high 
concentrations. The falloff at low concentration is due to increased variablility of the 
signal, whereas at high concentrations, it is due to saturation of the signal. 
As dChip is the only free software for academic uses from the above discussions, 
and the performance of different analysis methods are similar in quantifying 
transcript expressions according to the above discussions, we chose it to analyze the 
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data generated from Affymetrix GeneChip® array in our experiments. Since 
quantitative real-time PCR would be pro formed to validate the microarray results and 
probe sets with too high or too low concentrations can be ignored after analysis, the 
problem due to comparatively high false positive rate generated by dChip can be 
minimized to certain extent. 
4.2 Validation of microarray data 
The gold standard for validation is real-time PCR. There have been abundant 
studies used quantitative real-time PCR to validate their microarray results. The 
real-time PCR system is based on the detection and quantitative of a fluorescent 
reporter. This signal increases in direct proportion to the amount of PCR product in a 
reaction. By recording the amount of fluorescence emission at each cycle, it is 
possible to monitor the PCR reaction during exponential phase where the first 
significant increase in the amount of PCR product correlates to the initial amount of 
target template. 
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4.2.1 Advantages of using real-time PCR for mRNA quantification 
There are four methods commonly used for the quantification of transcription; 
northern blotting and in situ hybridization (Parker and Barnes, 1999), RNase 
protection assays (Hod 1992; Saccomanno et al., 1992) and the reverse transcription 
polymerase chain reaction (RT-PCR) (Weis et al, 1992). Northern analysis is the 
only method providing information about the mRNA size, alternative splicing and 
the integrity of RNA samples. The RNase protection assay is most useful for 
mapping transcript initiation and termination sites and intron/exon boundaries, and 
for discriminating between related mRNAs of similar size, which would migrate at 
similar positions on northern plot. In situ hybridization is the most complex method 
of all, but is the only one that allows localization of transcripts to specific cells 
within a tissue. The main limitation of these three methods is their comparatively low 
sensitivity (Melton et al., 1984). 
RT-PCR is an in vitro method for enzyniatically amplifying defined sequences 
of RNA (Rappolee et al., 1988) and permits the analysis of different samples from as 
little as one cell in the same experiment. It is the most sensitive and the most flexible 
of the quantification methods (Wang and Brown, 1999) and can be used to compare 
the levels of niRNAs in different sample populations, to characterize patterns of 
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mRNA expression, to discriminate between closely related mRNAs, and to analyze 
RNA structure. There are two PRC methods measuring the mRNA level: 
conventional PCR and real-time PCR. The amount of final amplified product by 
conventional PCR is measured at end-point, usually by electrophoretical separation 
of amplified DNA. In contrast, real-time PCR collects data in the exponential growth 
phase, it monitors the fluorescence emitted during the reaction as an indicator of 
amplicon production during each PCR cycle. Therefore, it eliminates post-PCR 
processing of PCR products, this helps to increase throughput and reduce the chances 
of carryover contamination. In addition, real-time PCR offers a much wider dynamic 
range in comparison to conventional RT-PCR. Consequently, real-time PCR 
provides a more sensitive and accurate quantitative method for measuring mRNA 
level. 
4.2.2 Comparison of mRNA gene expression by RT-PCR and DNA 
microarray 
There was a good correlation between the microarray and real-time PCR 
analyses even though there was no precise quantitative agreement in gene expression 
between the two techniques. Agreement between the two techniques dependent upon 
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the separation between the PCR primers and the microarray probes, as well as the 
number of absent calls by the microarray software has been well documented 
(Etienne et al., 2004). There would be a good agreement for the measurement of 
mRNA gene expression between real-time PCR and DNA microarray for genes with 
moderate levels of expression that have PCR primers located close to the microarray 
probes. Genes with very high or low levels of expression, or those with larger 
separation between the location of the PCR primers and microarray probes, often had 
reduced agreement between the two methods. Since our choice of PCR primers 
varied from gene to gene with respect to the position of the microarray probe, the 
discrepancy in absolute fold changes between the microarray analysis and 
quantitative real-time PCR is not totally unexpected. 
4.3 Gene expression profiling in serous ovarian cancer compared with normal 
ovarian epithelium 
We found that hierarchical clustering of samples and gene expression levels 
within samples led to the unambiguous separation of ovarian serous cancer from 
normal ovarian epithelium. We detected 392 genes differentially expressed between 
ovarian serous cancer and normal ovarian epithelium whose average change in 
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expression level between the two groups was at least 4-fold and which were 
significant with t-test at 99 % confidence interval. The cut-off value was set to 4-fold 
instead of commonly used 2-fold as we wanted to obtain a list of genes with higher 
stringency. The know function of some of these genes may provide insights in the 
biology of serous ovarian tumor, while others may prove to be useful diagnostic and 
therapeutic markers against normal ovarian epithelium. 
From our findings, half of the annotated genes were characterized as 
development, organogenesis, cell adhesion and oncogenesis. It implies that most of 
the genes differentially expressed in ovarian cancer take part in the biological 
processes specifically aimed at the progression of an organism over time from an 
initial condition (e.g. a zygote, or a young adult) to a later condition (e.g. a 
multicellular animal or an aged adult), processes by which anatomical structures are 
generated and organized, and the attachment of a cell, either to another cell or to the 
extracellular matrix, via cell adhesion molecules. Disruption of these processes 
would result in undifferentiated or immature cells, which are the characteristics of 
cancer cells. It showed that the genes take part in these biological processes would be 
impartant in tumorigenesis of ovarian cancer. It provides a clue in choosing genes for 
further validation as diagnostic, prognostic markers and therapeutic targets. It also 
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facilitates the further investigation in the pathway of tumorigenesis and therapeutic 
drugs design as the mechanism of drugs could be understood more easily when we 
focus on these biological processes. Moreover, genes involved in oncogenesis were 
also characterized, it revealed that our results was reliable in screening genes in 
carcinogenesis of ovarian cancer. Moreover, our data were comparable with those 
obtained from other groups. A group of genes we obtained were overlapped with the 
genes found by other groups using microarray to do gene expression profiling of 
ovarian cancers. The directions of fold change of the genes were in consistent with 
their results as well. It further revealed that our data were reproducible highly. 
4.3.1 Potential biomarkers or therapeutic targets in ovarian cancer 
Many of the differentially regulated genes from our results are well 
characterized and have widely varying functions, including mitotic cell cycle, cell 
adhesion and oncogenesis. For example, TTK, CDKNIC and BIRC5 are involved in 
oncogenesis. Among them, the BIRC5 gene showed very high expression level in 
serous ovarian cancer, with over 100-fold up-regulation in average relative to normal 
ovarian epithelium. 
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BIRC5 encodes a murine homologue of human Survivin, which is a member of 
the inhibitor of apoptosis (lAP) gene family (Ogasawara et al., 2001). lAP family 
encodes negative regulatory proteins that prevent apoptotic cell death. lAP family 
members usually contain multiple baculovirus lAP repeat (BIR) domains, but this 
gene encodes proteins with only a single BIR domain. Survivin inhibits apoptosis, 
via its BIR domain, by either directly or indirectly interfering with the function of 
caspases (Kobayashi et al., 1999). Survivin expression is highly cell cycle-regulated, 
and is detectable in the nucleus selectively at the G2/M phase (Li et al, 1998). Its 
gene expression is high during fetal development and in most tumors yet low in adult 
tissues. Survivin is expressed in most human cancers including that of colon, breast, 
lung, pancreas, prostate, stomach, esophagus, and in high-grade non-Hodgkin's 
lymphoma (Ambrosini et al., 1997; Ikeguchi et al., 2002; Yu et al., 2002). In all of 
these studies, survivin was not found in normal, adult tissues. Few studies were done 
on epithelial ovarian cancer, the findings suggested that survivinn over-expression 
always accompanied with poor prognosis (Takai et al., 2002; Sui et al., 2002). 
Recently, there has been great interest in survivin as a diagnostic marker and 
potential drug target because of its predominantly cancer-specific expression in adult 
human organ tissues. These data combined with our findings suggests that BIRC5 
may be a prognostic marker for ovarian cancer and may be targeted for therapeutic 
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purpose. 
TTK (also known as Mpsl) was identified as a dual specificity protein kinase 
that phosphorylates tyrosine or serine/threonine residues (Mills et al , 1992; Lindberg 
et al., 1993). Our data showed that it was highly expressed in ovarian cancers, which 
was more than 60-fold up-regulated in serous ovarian cancer compared with normal 
ovarian epithelium. Preliminary studies have shown that expression of TTK is 
detectable in all actively proliferating human cells and tissues, and thus it seems to be 
associated with cell proliferation (Mills et a l , 1992; Hogg et al., 1994; Schmandt et 
al., 1994). In addition, the Mpsl family is required for the spindle assembly 
checkpoint and centrosome duplication (Fisk et a l , 2001). Studies indicated that the 
Mpsl family of kinases colocalizes with kinetochores, whose activity is necessary to 
establish and maintain the checkpoint (Abrieu et al., 2001; Castillo et al , 2002). 
Therefore, the over-expression of TTK wouid increase the cell proliferation and 
influence the cell-cycle checkpoint regulation. These data suggests that TTK may 
play an important role in carcinogenesis of ovarian cancer. 
CDKNIC, encoding a protein known as 卩57乂丨口2，belongs to the CIP/KIP family 
of cyclin-dependent kinase inhibitors (CDKIs). pS?'^ '''^  is a 57 kD protein that inhibits 
cell cycle progression by binding to CDK2, -3，and - 4 (Lee et al., 1995; Matsuoka et 
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al., 1995). Overexpressing leads to Gi phase cell cycle arrest. It demonstrates 
a restrictive distribution in placenta, muscle, heart, brain, lung and kidney. CDKNIC 
is located on human chromosome 1 lpl5.5 (Matsuoka et al , 1995), a region which 
frequently undergoes loss of heterzygosity or mutations in several human cancers, 
including Wilms' tumor (Koufos et al, 1989)，rhabdomyosarcoma (Scrable et al., 
1989)，breast (Takita et al., 1992), liver (Fujimori et al., 1991) and bladder (Fearon et 
al., 1985) cancers. Furthermore，it was found that 戸57让丨口2 expression might play a 
pivotal role in the progression of ovarian tumors. Low pS?'^ '^ ^ expression was 
significantly associated with high tumor grades and advanced clinical stages (Sui et 
al., 2002). Our real-time validation result showed that this gene was down-regulated 
in more than 70% of serous ovarian cancer samples compared with normal ovarian 
epithelium by 2-fold. However, it is difficult to use a down-regulated gene as a 
diagnostic or prognostic marker. The combination of use of multiple markers would 
increase the sensitivity and specificity of diagnosis or prognosis. Therefore, 
CDKNIC may be added to know marker of ovarian cancer and may combine with 
current diagnostic or prognostic marker in screening and follow-up the disease. 
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4.4 Gene expression profiling in advanced serous ovarian cancer compared 
with early ovarian cancer 
From the microarray analsysis, we detected 10 genes differentially expressed 
between advanced ovarian serous cancer and early ovarian cancer whose average 
change in expression level between the two groups was at least 2-fold and which 
were significant with t-test at 99% confidence interval. Of the ten genes, there are 
genes involved in calcium binding (e.g. CLGN, LRP8 and EGFL6), integrin binding 
(e.g. STXBP6) and extracellular matrix structural constituent (e.g. C0L13A1). Cell 
adhesion is to a large extent a Ca^"^-regulated process. Alterations in the extracellular 
1 
Ca concentration have a direct impact on the adhesive behavior of epithelial cells 
(Aspenstrom, 2004). Integrin binding and extracellular matrix structural constituent 
proteins are directly involved in cell adhesion processes. It implies that our data 
represents genes involved in progression of ovarian cancer. 
We found that the unsupervised hierarchical clustering of samples and gene 
expression levels within samples did not show an unambiguous separation of 
advanced-stage ovarian serous cancers form early-stage ovarian cancers. This may be 
due to the small samples size of early-stage (n = 8) and advanced-stage (n = 20) 
ovarian cancer in performing microarray analysis. Our real-time PCR results, 
4 - 16 
Getjs expression profiling of ovarian cancer Chapter 4. Discussions 
however, displayed the same direction of fold change as in microarray results. This 
implies that our results are reliable. 
4.4.1 Potential prognostic markers or therapeutic targets in advanced ovarian 
cancer 
EGFL6 encodes a member of the epidermal growth factor (EGF) repeat 
superfamily (Yeiing et al., 1999). Members of this superfamily are characterized by 
the presence of EGF-like repeats and are often involved in the regulation of cell 
cycle, proliferation, and developmental processes (Appella et al , 1988). The gene 
product contains a signal peptide, suggesting that it is secreted (Yeung et al., 1999). 
Secreted protein is ideal to be used as diagnostic and prognostic marker. In addition, 
an EGF repeat region of this gene consists of 4 complete EGF-like repeats and 1 
partial EGF-like repeat, 3 of which have a caicium-binding consensus sequence; an 
arg-gly-asp integrin association motif; and a MAM (meprin/A5-protein/PTPmu) 
domain, which is believed to have an adhesive function (Buclmer et al., 2000). The 
de-regulation of cell adhesion may increase the invasiveness of cancer cells and lead 
the cancer to progress. Furthermore, EGF motif-containing molecules have been 
previously linked to the progression of various cancers, such as pancreatic cancer 
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(Birk et al , 1999) and lung cancer (Dave et al., 1996), it indicates that EGFL6 may 
also be linked to cancer progression. Our data showed that EGFL6 was significantly 
over-expressed in advanced ovarian cancer compared to early serous ovarian cancer 
by more than 10-fold, and more than 70% of advanced serous ovarian cancer had at 
least 2-fold change. Our findings combined with the previous studies on EGFL6 
suggest that EGFL6 may delineate aggressive ovarian cancer disease and may be 
targeted for therapeutic and/or diagnostic purposes. 
COL13A1 encodes the alpha chain of one of the nonfibrillar collagens 
(Pihlajaniemi et al” 1990). The function of this gene product is not well known, 
however, it has been detected at low levels in all connective tissue-producing cells so 
it may serve a general function in connective tissues. Unlike most of the collagens, 
which are secreted into the extracellular matrix, collagen XIII contains a 
transmembrane domain and the protein has been localized to the plasma membrane 
(Kvist et al., 1999). Like other collagens, collagen XIII is a trinier, type XIII collagen 
produced in insect cells forms 'xl(XIII) homotrimers, and the three collagenous 
domains fold into a stable triple helical conformation (Snellman et al , 2000). It is 
shown that type XIII collagen has an important role in certain adhesive interactions 
that are necessary for normal development (Sund et al., 2001). Our data also showed 
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that C0L13A1 was over-expressed in advanced stage ovarian cancers compared to 
early ovarian cancers. Therefore, although studies on the type XIII collagen linked to 
cancer progression were not well documented, it may be a potential prognositc 
marker for ovarian cancer if further validation of this gene in ovarian cancer is done. 
PEG 10, the paternally expressed gene 10, is an imprinted gene, suggesting a 
role in embryonic development (Ono et al., 2001). PEGIO was recently found to be 
highly expressed in hepatocellular carcinoma and in regenerating mouse liver where 
it was induced in G2/M phase (Tsou et al, 2003; Okabe et al , 2003). It has two 
overlapping open reading frames (ORFl and 0RF2), the protein products from these 
two ORFs of PEGIO shows homology to the gag and pol proteins of vertebrate 
retrotransposon Ty 3/Gypsy, therefore PEGIO is speculated to be a 
retrotransposon-derived gene (Ono et al.，2001). Cell migration and spreading require 
the involvement of cytoskeletal and focal adhesion proteins. PEGIO-RFI might 
function as an adaptor/scaffolding protein that connects ALKl with cytoskeletal or 
focal adhesion proteins (Lux et al., 2005). The interaction of ALKl with PEGIO-RFI 
might link ALKl to cell adhesion/migration processes. We also found that PEGIO 
was up-regulated in advanced ovarian cancers compared to early ovarian cancers. 
Therefore, PEGIO might be added to known prognostic markers. 
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STXBP6 encodes a brain-enriched syiitaxin-binding protein, named amisyn. 
The precise function of amisyn remains unclear. It has been suggested that amisyn 
has a tomosyn-like SNARE domain that binds in vitro and in vivo to syntaxin 1 at the 
plasma membrane and may regulate SNARE complex formation (Scales et al., 2002). 
The regulation of SNARE complex assembly likely plays an important role in 
governing the specificity as well as the timing of membrane fusion. Structurally the 
SNARE complex is a four-helix bundle comprised of one coiled-coil-forming domain 
from each of syntaxin and VAMP and two from SNAP-25 (Poirier et al., 1998; 
Sutton et al. 1998). It was proposed that the formation of SNARE drives the mixing 
of the membrane bilayers by zippering up through the transmembrane domains of 
syntaxin and VAMP (Hanson et al , 1997; Lin et al., 1997). Amisyn has similarity in 
its coil domain to tomosyn and VAMPS and that also binds to syntaxins 1 and 4 and 
therefore may play a role in regulating the formation of SNARE complexes. In 
addition to mediating the fusion event, the SNARE proteins have also been 
implicated in the specificity of membrane fusion, the SNARE hypothesis stating that 
a particular v-SNARE on a transport vesicle should only form a specific complex 
with its cognate t-SNARE on the correct target membrane, thereby ensuring that the 
vesicles only fuse with the right compartment (Rothman, 1994). 
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It has been suggested that inhibition of SNARE-mediated traffic resulted from 
both a reduction in the level of integrin on the cell surface and a disruption of 
membrane remodeling that contributes to defect in cell migration (Tayeb et al., 2005). 
It implies that over-expression of amisyn may result in excessive SNARE complex 
which may promote cell migration. Our data presented that the amisyn was 
over-expressed in advanced stage ovarian cancer compared to early stage ovarian 
cancer. Therefore, STXBP6 may be a valuable potential prognostic marker of 
ovarian cancer. 
PLOD2 encodes a membrane-bound homodimeric enzyme telopeptide lysyl 
hydroxylase (TLH) that is localized to the cistemae of the rough endoplasmic 
reticulum. It has been proposed that PLOD2 is involved in fibrotic processes (van 
der Slot et al., 2003). The hallmark of fibrotic processes is an excessive accumulation 
of collagen. TLH catalyzes the hydroxylation of lysyl residues in collagen-like 
peptides. The resultant hydroxylysyl groups are attachment sites for carbohydrates in 
collagen and thus are critical for the stability of collagen intennolecular crosslinks. 
Collagens are usually involved in cell adhesion at basement membrane by binding to 
integrins. However, our data showed that PL0D2 was up-regulated in advanced 
ovarian cancers compared to early ovarian cancers. The biological processes and 
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molecular functions involved by PLOD2 have to be investigated in order to figure 
out the exact role of PLOD2 in ovarian cancer progression. 
4.5 Gene expression profiling in metastatic cancer compared with primary 
ovarian cancer 
In microarray analysis, only two genes were obtained by using 2-fold change as 
cut-off value. Therefore, we released the cut-off value to 1.5-fold in order to see 
more genes that are differentially regulated although they may have only subtle 
change in expression in metastatic cancers of ovary origin compared with primary 
ovarian cancers. We detected 20 genes differentially expressed between metastatic 
cancer and primary ovarian cancer whose average change in expression level 
between the two groups was at least 1.5-fold and which were significant with t-test at 
95% confidence interval. Of the 20 genes we found, some genes were involved in 
cell adhesion (e.g. TNC and TPBG), cell proliferation (e.g. EMPl and NEDD9) and 
regulation of transcription (e.g. EGRl and PAPOLA). Deregulation of cell adhesion 
will cause detachment of cancer cells from their original localization and hence 
migration of cancer cells to other sites. These are the main hypothetic processes of 
cancer metastasis. Also, uncontrolled cell proliferation is main feature of cancer cells. 
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And deregulated transcription may result in aberrant expression of cancer-related 
and/or metastasis-related genes. Therefore, our results did show the differentially 
expressed genes related to metastasis of ovarian cancer. 
From our result of real-time PCR validation, the trend of fold changes was in 
the same direction with microarray result, although there were variations between the 
two experiments. We found that the unsupervised hierarchical clustering of samples 
and gene expression levels within samples did not show an unambiguous separation 
of metastatic cancers from primary ovarian cancers. This may be due to the small 
samples size of metastatic (n = 4) and primary (n = 4) ovarian cancer in microarray 
analysis. 
4.5.1 Potential predictive markers or therapeutic targets in metastatic cancer 
of ovary origin 
TNC encodes the large hexameric glycoprotein tenascin-C (TN-C) found in the 
extracellular matrix (Chiquet-Ehrismann et al, 1986; Erickson and Bourdon, 1989). 
It is thought to be involved in numerous cellular functions including adhesion, 
migration, embryonic development, wound healing and tumor metastasis (Erickson 
4 - 23 
Getjs expression profiling of ovarian cancer Chapter 4. Discussions 
and Bourden, 1989; Chiquet-Ehrismann, 1993). It is strongly expressed in 
developing fetal tissues, while in mormal adult tissues and organs its expression is 
generally limited to areas associated with proliferation and cellular re-organization 
(Wilson et al., 1999). Each monomer of TN-C consists of five components: a central 
domain, heptad repeats, epidermal growth factor (EGF)-like repeats, fibronectin type 
III repeats and a fibrinogen-like sequence. During malignant invasion and metastasis 
the processes of both adhesion and anti-adhesion are important. TN has been shown 
to contain both adhesive (within its alternatively spliced region) and anti-adhesive 
element (within the EGF-like repeat structures) (Spring et al., 1989). These opposing 
activities arise as a consequence of tenascins binding to other components of the 
extracellular matrix (ECM) and to cell surface receptors. The effect of a tenascin on a 
single cell type may vary depending on the cell's contact with other ECM 
components (Jones et al., 2000). Cell surface receptors for the tenascins include 
members of the integrin family of heterodimers, cell adhesion molecules (CAMs) of 
the immunoglobulin superfamily, an unusual transmembrane chondroitin sulfate 
proteoglycan/receptor protein tyrosine phosphatase, and annexin II. TN-C also 
interacts with other extracellular proteins, including fibronectin, and also bind with 
high affinity to a class of extracellular chondroitin sulfate proteoglycans called the 
lecticans (aggrecan, versican, brevican, aiid neurocan). Furthermore, tenascins 
4 - 24 
Getjs expression profiling of ovarian cancer Chapter 4. Discussions 
interact with and are cleaved by serine proteinases and matrix metalloproteinases. All 
these findings suggest that TNC may play an important in cell adhesion. 
De-regulation of this gene may result in disruption of cell adhesion mechanisms. 
The functional activities provided by tenascin proteins may occur through direct 
interactions with cell surface receptors or indirectly through modulation of other 
ECM proteins and cell-cell adhesion molecules. Recent experiments indicate that the 
mechanism is specific but indirect. Tenascin-C was first proposed either to sterically 
mask substrate-bound fibronectin (Lightner et al., 1990), or to interfere with binding 
of integrin c6/31 to fibronectin (Chiquet-Ehrismann et al., 1988). Larger variants of 
TN-C have been correlated with cell migration and invasiveness of carcinomas 
(Prieto et al.，1990; Kaplony et al , 1991), including malignant ovarian tumors 
(Wilson et al., 1996). These findings provide clues that certain domains of TN-C 
may be essential for malignant tumor progression. 
Our data also showed that TNC was over-expressed in metastatic cancer of 
ovary origin by almost 10-fold compared to primary serous ovarian cancer. It further 
suggests that future research assessing its clinical usefulness in monitoring the 
metastasis process of ovarian cancer would be worthwhile. 
PLAU encodes a serine protease, urokinase-type plasminogen activator (uPA), 
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involved in degradation of the extracellular matrix and possibly tumor cell migration 
and proliferation. The protein encoded by this gene converts inactive zymogen 
plasminogen to active proteinase plasmin, which is able to degrade many 
extracellular matrix proteins important for cell adhesion and migration, such as 
fibronectin (FN), vitronectin (VN) and fibrin. The active plasmin can also catalyze 
activation of the zymogen forms of several metalloproteinases (Andreasen et al., 
1997). Over-expressed uPA may result in high level of proteinase plasmin and 
eventual clearance of the extracellular matrix proteins. Consequently, cells may lose 
their connection bridge and promote cell migration. 
uPA was the first proteinase shown to be a prognostic marker in human 
malignancy. iiPA antigen levels appear to be among the strongest prognostic factors 
so far described for breast cancer (Andreasen et al , 1997). Apart from breast cancer, 
uPA has been shown to be a prognostic marker in other malignancies, including 
cancers of the lung (Oka et al., 1991)，bladder (Hasui et al , 1992)，cervix (Kobayashi 
et al., 1994), kidney (Hofmann et al., 1996) and ovary (Kuhii et al., 1994). However, 
data of most of the non-breast malignancies are still preliminary and in some cases 
mutually conflicting. Our data also showed that uPA was over-expressed in 
metastatic cancers of ovary origin compared to primary ovarian cancers. Therefore, 
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further investigation of this gene in the role cancer metastasis may add its value in 
prognosis of ovarian cancer. 
SERPINEl encodes the protein plasminogen activator inhibitor type 1 (PAI-1), 
which is the main inhibitor of the urokinase-type plasminogen activator (uPA) and 
tissue-type plasminogen activiator (tPA). PAI-1 belongs to the SERPIN-superfamily 
of serine proteinases inhibitors and represents a key regulatory protein in proteolytic 
processes responsible for tissue remodeling and tumor metastasis. Many studies have 
shown that high expression of PAI-1 in ovarian cancer correlates rather with 
unfavorable than favorable prognosis (Chambers et al., 1998; Kuhn et al., 1999). 
Many ensuing clinical and mechanistic studies generated many paradoxical 
results concerning the mechanism of PAI-1 function and its role as the cause, or 
merely the effect, of increased cell migration (Vaughan, 2002). The cause of these 
controversies lies in the promiscuous behavior of PAI-1. PAI-1 is a dual function 
protein that inhibits the activation of plasminogen on one hand and interferes with 
cell binding to vitronectin on the other hand (Chapman, 1997). It binds to PAs and 
inhibits their capability of catalyzing the conversion of the inactive zymogen 
plasminogen to the active proteinase plasmin, which can degrade most extracellular 
proteins (Andreasen et al., 1997). Meanwhile, PAI-1 is conformationally unstable 
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under physiological conditions (Hekman and Loskutoff, 1985) and is in turn 
regulated by binding to other proteins, which stabilize it in the active conformation. 
The major circulating PAI-1 binding protein is the adhesive glycoprotein vitronectin 
(VN), which is abundantly present in the extracellular matrix (Declerck et al, 1988; 
Wiman et al., 1988; Mimuro and Loskutoff, 1989). VN is an important extracellular 
matrix protein for cell adhesion and migration (Zheng et al., 1995). The binding of 
PAI-1 to VN, however, has been shown to block the interaction of integrins with VN, 
thereby loosening cells from their substratum and promoting cell migration 
(Stefansson and Lawrence, 1996; Deng et al, 2001; Czekay et al, 2003). This effect 
may be explained by the 3-demension structure determination of PAI-1 complexed to 
the somatomedin-B (SMB) domain of VN. The SMB domain is adjacent to only the 
integrin binding RGD sequence in VN (Tomasini and Mosher, 1991; Deng et al, 
1995), raising the possibility that PAI-1 inhibits integrin-mediated cell adhesion by 
binding to SMB and sterically blocking the adjacent RGD site (Stefansson and 
Lawrence, 1996). However, this hypothesis has not been tested experimentally. 
Nevertheless, Czekay et al. (2003) has shown that the deadhesive activity of PAI-1 
does not appear to require its interaction with VN, instead, there is an absolute 
requirement for its binding to the uPA present in uPA-uPAR-integrin (uPAR; uPA 
receptor) complexes on the cell surface. Interestingly, PAI-1 also detaches cells from 
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fibronectin (FN) and type I collagen by a similar uPA/uPAR-dependent mechanism 
(Czekay et al., 2003). These observations suggest that cell detachment by PAI-1 may 
represent a general mechanism for the release of cells from the extracellular matrix. 
Yet another role of PAI-1 in cancer is envisioned in tumor-induced angiogenesis, an 
essential process for tumor survival and growth (McMahon et al, 2001; Stefansson et 
al, 2001). Angiogenesis will only proceed efficiently when PAI-1 levels are within an 
optimal range. In PAI-1 excess, the vitronectin matrix remains saturated with PAI-1, 
and integrin adhesion is blocked. These all suggest that PAI-1 plays an important role 
in metastasis of ovarian cancer, yet the actual mechanism should be further 
investigated in order to solve the paradox. 
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CHAPTER 5 CONCLUSIONS 
We have demonstrated the utility of oligonucleotide microarrays in analyzing 
the molecular changes in ovarian cancer, a complex biological system. This approach 
has the additional attribute of analyzing multiple tumor samples in a rapid fashion. 
Also, the data obtained are comparable to those obtained by other groups. 
In this study, clusters of genes involved in tumorigenesis, cancer progression 
and cancer metastasis in ovarian cancer have been revealed. Some of these genes 
have been previously found to be highly expression in ovarian cancer, while others 
have not been reported in this disease. Based on ontology analysis, we found the 
genes involved in "development, organogenesis, cell adhesion and oncogenesis" 
were mostly differentially regulated in ovarian cancer. Of the 15 genes that were 
selected for real-time PCR validation, four genes, CDC2, CKDNJC, DIRAS3 (ARHI) 
and TOP2A, were previously reported differentially expressed in ovarian cancer, 
eight genes, BJRC5, BUBIB, CCNAl, CCNB2, CCNEl, NEK2, T0P2A and TTK, 
were previously reported differentially expressed in other cancers and four 
genes ’HCAP-G’ KNTC2, KPNA2 and REC8L1, were not well documented in 
cancers. We also found the genes involved in "calcium binding, integrin binding and 
extracellular matrix structural constituent" were mostly differentially regulated in 
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advanced stage ovarian cancer compared to early stage ovarian cancer, while genes 
involved in "cell adhesion, cell proliferation and regulation of transcription" were 
mostly differentially regulated in metastatic cancer of ovary origin compared to 
primary ovarian cancer. In the eight genes that were selected for real-time PCR 
validation, three genes, TNC’ PLAU and SERPINEl, were previously reported 
related to progression and/or metastasis in ovarian cancer, two genes ,EGFL6 and 
PEGIO, were previously reported related to progression in other cancers, three genes, 
COL 13A, STXBP6 and PL0D2, were not well documented related to progression or 
metastasis in cancers. 
Totally, we have identified seven dysregulated genes that were previously 
described in ovarian cancers. The repeated identification of the above genes as 
aberrantly expressed in ovarian cancers using multiple platforms suggests that these 
genes may form the basis for the development of diagnostic, and prognostic markers 
as well as novel therapy. For the list of genes that were not previously associated 
with ovarian cancer, further investigation of their functional role in the development 
and progression of ovarian cancer is warranted. 
Alterations in gene expression in ovarian tumors may yield clues to their 
pathogenesis and invasiveness. Analysis of a larger number of ovarian cancer 
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specimens and correlation with biological phenotypes with gene expression patterns 
may identify clinically meaningful characteristics of this common gynecologic 
malignancy. This could provide important clues to develop novel diagnostic and 
prognostic markers as well as strategies for efficient prevention and therapy for 
ovarian cancer. 
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CHAPTER 6 FUTURE PROSPECT 
In order to further investigate the feasibility of the candidate genes to be 
diagnostic or prognostic tumor markers, studies on the genes in protein level should 
be carried. In situ immunostaining should be performed to localize the expression of 
the candidate genes. By this method, the location of the protein products can be 
visualized. Moreover, if the proteins are secreted into blood stream, ELISA can be 
done in an attempt to test the protein level of the candidate genes in serum of patients. 
It is important that a tumor marker can be evaluated in serum. In addition, siRNA can 
be carried in order to study the involved pathway of the candidate genes. The goal of 
pathway elucidation is to look for therapeutic targets and better design therapeutic 
drugs in chemotherapy or gene therapy. 
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